fluorouracil has been researched along with flucytosine in 219 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 38 (17.35) | 18.7374 |
| 1990's | 34 (15.53) | 18.2507 |
| 2000's | 82 (37.44) | 29.6817 |
| 2010's | 54 (24.66) | 24.3611 |
| 2020's | 11 (5.02) | 2.80 |
| Authors | Studies |
|---|---|
| Gershon, H; Shanks, L | 1 |
| Becker, JM; Naider, F; Steinfeld, AS | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Dannaoui, E; Dromer, F; Janbon, G; Lortholary, O; Schwarz, P | 1 |
| Chapeland-Leclerc, F; Chastin, C; Florent, M; Gibot-Leclerc, S; Jean, D; Noël, T; Papon, N; Villard, J | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Coleman, DC; Higgins, JA; McManus, BA; Moran, GP; Sullivan, DJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Betina, V; Zajacová, J | 1 |
| Rees, RB | 1 |
| Shadomy, S; Wagner, GE | 1 |
| Oliver, SG; Williamson, DH | 2 |
| Berenbaum, MC | 1 |
| Barylak, J; Pawlik, B | 1 |
| Cook, AF; Holman, MJ; Kramer, MJ; Trown, PW | 1 |
| Bennett, JE; Diasio, RB; Lakings, DE | 1 |
| MacCoss, M; Naik, SR; Ramani, G; Robins, MJ | 1 |
| Burchenal, JH; Currie, VE; Dowling, MD; Fox, JJ; Krakoff, IH | 1 |
| Fraenkel-Conrat, H; Gleason, MK | 1 |
| Andreassi, L; Fimiani, M; Ottolenghi, F; Sbano, E | 1 |
| Graf, W; Holmgren, B | 1 |
| Bonazzi, D; Cavrini, V; Di Pietra, AM | 1 |
| Fasoli, MO; Kerridge, D; Morris, PG; Torosantucci, A | 1 |
| Heidemann, HT; Holzlöhner, U; Inselmann, G | 1 |
| Blumenkranz, MS; Hajek, AS; Hartzer, MK | 1 |
| Fasoli, M; Kerridge, D | 1 |
| Carlucci, G; Maurizi, G; Mazzeo, P; Quaglia, MG | 1 |
| Fernex, M; Keller, P; Kissling, M | 1 |
| Hou, XQ; Hu, YZ; Jiang, SH; Li, FW; Zhang, YH | 1 |
| Carpinelli, G; Cassone, A; Di Vito, M; Kerridge, D; Podo, F; Torosantucci, A; Whelan, WL | 1 |
| De Clercq, D; De Vroey, C | 1 |
| Diasio, RB; Federle, TW; Harris, BE; Manning, BW | 1 |
| Chouini, N; Lepargneur, JP; Malet-Martino, MC; Martino, R; Michel, G; Vialaneix, JP | 1 |
| Bernard, E; Chichmanian, RM; Dellamonica, P; Fournier, JP; Garraffo, R; Lapalus, P; Le Fichoux, Y; Marty, P | 1 |
| Ito, T; Katsuragi, T; Kawamoto, K; Kawamura, Y; Matsumura, H; Nishiyama, T; Ohyama, A; Sakai, T; Yamamoto, N | 1 |
| Drouhet, E; Mercier-Soucy, L; Montplaisir, S | 2 |
| Beck, CF; Ingraham, JL; Neuhard, J; Thomassen, E | 1 |
| Lipkin, M; Troncale, FJ | 1 |
| Polak, A | 2 |
| Devaney, E; Howells, RE; Smith, G; Tinsley, J | 1 |
| Myers, CE | 1 |
| Dźwigaj-Stokłosa, W; Hołuj-Gubała, J; Pawlik, B | 1 |
| Crystal, RG; Hirschowitz, EA; Ohwada, A; Pascal, WR; Russi, TJ | 1 |
| Gutierrez, AA; Harris, JD; Hurst, HC; Lemoine, NR; Sikora, K | 1 |
| Hisajima, S; Ichikawa, H; Kobayashi, T; Stougaard, J | 1 |
| Chang, CN; Chang, CP; Chen, HX; Cheng, YC; Guo, X; Lerner-Tung, M; Lin, TS; Pizzorno, G; Zhu, JL | 1 |
| Austin, EA; Davis, ST; Good, SS; Huber, BE; Richards, CA | 1 |
| Cosand, WL; Kerr, DE; MacMaster, JF; Senter, PD; Smith, VF; Wallace, PM | 1 |
| Linard, CG; Perera, RJ; Signer, ER | 1 |
| Austin, EA; Good, SS; Huber, BE; Knick, VC; Richards, CA; Tibbels, S | 1 |
| Austin, EA; Huber, BE | 1 |
| Gebert, J; Haack, K; Haberkorn, U; Lindauer, M; Morr, I; Oberdorfer, F; Schackert, HK; van Kaick, G; Weber, K | 1 |
| Gebert, JF; Haberkorn, U; Herfarth, C; Lindauer, M; Moebius, U; Oberdorfer, F; Rowley, S; Schackert, HK | 1 |
| Bhatia, K; Judde, JG; Magrath, I; Spangler, G | 1 |
| Brown, JM; Davis, TO; Fox, ME; Giaccia, AJ; Lemmon, MJ; Mauchline, ML; Minton, NP | 1 |
| Hamada, H; Kanai, F; Lan, KH; Ohashi, M; Okabe, S; Omata, M; Shiratori, Y; Tanaka, T; Wakimoto, H; Yoshida, Y | 1 |
| Belhumeur, P; Cousineau, L; Lemay, G; Mercure, S; Montplaisir, S | 1 |
| Dachs, GU; Firth, JD; Harris, AL; Patterson, AV; Ratcliffe, PJ; Stratford, IJ; Townsend, KM | 1 |
| Allain, P; Boisdron-Celle, M; Gamelin, E; Larra, F; Robert, J; Turcant, A | 1 |
| Aghi, M; Breakefield, XO; Chiocca, EA; Chou, TC; Kramm, CM | 1 |
| Crystal, RG; Hackett, NR; Topf, N; Worgall, S | 1 |
| Freytag, S; Gabel, M; Khil, M; Kim, JH; Kolozsvary, A | 1 |
| Adams, E; Brown, R; Burtness, B; Cooperberg, MR; Cote, R; Crystal, R; Deisseroth, AB; Fu, SQ; Garcia-Sanchez, F; Giles, R; Hanania, E; Krause, DS; Leffert, JJ; Liang, J; Nanakorn, T; Peng, XY; Pizzorno, G; Wang, WL; Won, JH; Yin, LH | 1 |
| Aboagye, EO; Artemov, D; Bhujwalla, ZM; Senter, PD | 1 |
| Ge, K; Liu, XY; Sun, LY; Xu, LF; Zheng, ZC | 1 |
| Baron, M; Cazaux, C; Drocourt, D; Reynes, JP; Tiraby, G; Tiraby, M | 1 |
| Arnold, W; Dörken, B; Körner, IJ; Mapara, MY; Schumacher, A; Wolff, G | 1 |
| Bershad, E; Dev, I; Kievit, E; Lawrence, TS; Ng, E; Rehemtulla, A; Sethna, P | 1 |
| Guchelaar, HJ; van der Sijs, H; Vermes, A | 1 |
| Fukui, H; Ikenaka, K; Kikukawa, M; Kuriyama, S; Masui, K; Mullen, CA; Nakatani, T; Okuda, H; Sakamoto, T; Tsujii, T; Yoshiji, H | 1 |
| Beattie, B; Blasberg, RG; Kievit, E; Lawrence, TS; Rehemtulla, A; Ross, BD; Stegman, LD; Tjuvajev, JG | 1 |
| Morris, JC | 1 |
| Baqué, P; Bourgeon, A; Chazal, M; Gavelli, A; Gugenheim, J; Mala, M; Milano, G; Pierrefite-Carle, V; Rossi, B; Staccini, P | 1 |
| Altaner, C; Hlavatý, J; Hlubinová, K | 1 |
| Anné, J; De Bruijn, E; Fowler, J; Lambin, P; Landuyt, W; Nuyts, S; Theys, J; Van Mellaert, L | 1 |
| Anderson, LM; Krotz, S; Thimmapaya, B; Weitzman, SA | 1 |
| Alexander, HR; Bartlett, DL; Hu, Y; Lee, J; Libutti, SK; McCart, JA; Puhlmann, M | 1 |
| Bacich, DJ; Heston, WD; Martorana, A; Molloy, PL; O'Keefe, DS; Uchida, A; Watt, FB | 1 |
| Noble, M | 1 |
| Kievit, E; Lawrence, TS; Ng, E; Nyati, MK; Parsels, J; Rehemtulla, A; Ross, BD; Stegman, LD | 1 |
| Aihara, T; Kaneda, Y; Kanyama, H; Miyoshi, Y; Monden, M; Ohue, M; Sakita, I; Sekimoto, M; Senter, PD; Tamaki, Y; Tomita, N; Yamano, T | 1 |
| Guchelaar, HJ; Toraño, JS; Vermes, A | 1 |
| Olsen, BA | 1 |
| Crystal, R; Deisseroth, A; Fujii, T; Kacinski, B; Leavitt, J; Peng, XY; Pizzorno, G; Rutherford, T; Sapi, E; Schwartz, P; Won, JH; Zelterman, D | 1 |
| Anné, J; Lambin, P; Landuyt, W; Nuyts, S; Theys, J; Van Mellaert, L; van Oosterom, A | 1 |
| Aubertin, AM; Balzarini, J; De Clercq, E; Faraj, A; Gosselin, G; Griffon, JF; Mathé, C; Sommadossi, JP | 1 |
| Chandrasekhar, S; Mullen, JT; Nakamura, H; Pawlik, TM; Tanabe, KK; Yoon, SS | 1 |
| Cunningham, C; Nemunaitis, J | 1 |
| Anderson, D; Burton, A; Chen, MJ; Chung-Faye, GA; Green, NK; Kerr, DJ; Mautner, V; Searle, PF | 1 |
| Buchsbaum, DJ; Gillespie, GY; Miller, CR; Williams, CR | 1 |
| Baqué, P; Benchimol, D; Bourgeon, A; Brossette, N; Gavelli, A; Pierrefite-Carle, V; Rossi, B; Saint Paul, MC; Staccini, P | 1 |
| Brown, JM; Giaccia, AJ; Liu, SC; Minton, NP | 1 |
| Dankert, J; Guchelaar, HJ; van Kuilenburg, AB; Vermes, A | 1 |
| Nakanishi, T; Sekimizu, K | 1 |
| Akimoto, A; Akimoto, M; Arai, J; Hamada, H; Miyahara, T; Yoshida, Y; Yoshimura, N | 1 |
| Baqué, P; Benchimol, D; Bourgeon, A; Brossette, N; Gavelli, A; Pierrefite-Carle, V; Rossi, B; Saint-Paul, MC; Staccini, P | 1 |
| Belcourt, M; Bermudes, D; Ittensohn, M; King, I; Lang, W; Le, T; Li, Z; Lin, S; Luo, X; Mao, J; Pike, J; Runyan, JD; Troy, K; Zheng, LM | 1 |
| Bernt, KM; Li, ZY; Lieber, A; Ni, S; Roffler, SR; Steinwaerder, DS | 1 |
| Bauder-Wüst, U; Becker, G; Corban-Wilhelm, H; Debus, J; Greulich, D; Hull, WE | 1 |
| Hayakawa, M; Ikegami, S; Suzuki, S; Tadakuma, T; Yoshimura, I | 1 |
| Kato, H; Koshida, K; Mizokami, A; Namiki, M; Yokoyama, K | 1 |
| Amano, J; Fujimori, M; Kano, Y; Nakamura, T; Sasaki, T; Taniguchi, S; Yazawa, K | 1 |
| DeRemer, S; Ensminger, WD; Lawrence, TS; Li, S; Nyati, MK; Parsels, J; Rehemtulla, A; Zhang, M | 1 |
| Hsu, YH; Hu, CY; Ko, TP; Liaw, SH; Lin, JJ; Wang, AH | 1 |
| Dankert, J; Guchelaar, HJ; Kuijper, EJ; Vermes, A | 1 |
| Barresi, V; Belluardo, N; Cattaneo, E; Condorelli, DF; Mudò, G; Sipione, S | 1 |
| He, JQ; Liu, YS; Lv, SQ; Wang, B; Yang, H; Yoshimura, I | 1 |
| Cahill, A; Cavagnolo, R; Clairmont, C; Cramm, J; Cunningham, C; Kuhn, J; Litz, C; Nemunaitis, J; Senzer, N; Sznol, M | 1 |
| Clohisy, DR; Goblirsch, M; Lewis, V; Lynch, C; Mantyh, P; Orchard, P; Pan, W; Ramnaraine, M | 1 |
| Anné, J; de Bruijn, E; Dresselaers, T; Lambin, P; Landuyt, W; Nuyts, S; Theys, J; Van Hecke, P; Wouters, B | 1 |
| Barber, GN; Mian, A; Porosnicu, M | 1 |
| Craig, RK; Markaki, M; Savakis, C | 1 |
| Chung, I; Deisseroth, AB | 1 |
| Anderson, MJ; Denning, DW; Hope, WW; Tabernero, L | 1 |
| Chen, M; Chenevert, TL; Dornfeld, KJ; Gelovani, JT; Hamstra, DA; Lawrence, TS; Lee, KC; Moffat, BA; Rehemtulla, A; Ross, BD; Schepkin, VD; Tychewicz, JM | 1 |
| Bharara, S; Conrad, C; Fueyo, J; Gomez-Manzano, C; Ji, Y; Lang, FF; McMurray, JS; Miller, CR; Sawaya, R; Wong, F; Yung, WK | 1 |
| Deen, DF; Hu, L; Kong, EL; Lamborn, KR; Rehemtulla, A; Ruan, H; Wang, D | 1 |
| Li, Y; Liu, A; Wu, Y; Yan, H; Yao, L | 1 |
| Clohisy, DR; Pan, W; Ramnaraine, M | 1 |
| Liu, YS; Lü, SQ; Yang, H | 1 |
| Lawrence, TS | 1 |
| Bhojani, MS; Bullarayasamudram, S; Dornfeld, KJ; Hamstra, DA; Lee, KC; Moffat, BA; Rehemtulla, A; Ross, BD | 1 |
| Guentert, TW | 1 |
| Desmoulin, F; Gilard, V; Malet-Martino, M; Martino, R | 2 |
| Boucher, PD; Freytag, SO; Im, MM; Shewach, DS | 1 |
| Campbell, G; Coffin, RS; Han, Z; Liu, B; Simpson, GR; Wang, Y | 1 |
| Eslamifar, A; Salehi-Najafabadi, A; Tirandaz, H | 1 |
| Dresselaers, T; Dubois, L; Lambin, P; Landuyt, W; Mengesha, A; Paesmans, K; Theys, J; Van Hecke, P; Wouters, BG | 1 |
| Bourbeau, D; Jaime, J; Koty, Z; Lau, CJ; Lavoie, G; Massie, B; Mes-Masson, AM; Nalbantoglu, J; Zehntner, SP | 1 |
| Amano, J; Fujimori, M; Hamaji, Y; Kano, Y; Matsuhashi, H; Matsui-Seki, K; Sasaki, T; Shimatani-Shibata, Y; Taniguchi, S | 1 |
| Haga, K; Hiraoka, K; Kasahara, N; Kimura, T; Lawson, GW; Logg, CR; Tai, CK | 1 |
| Coelho, V; Deckert, PM; Dernedde, J; Dübel, S; Fuchs, H; Keilholz, U; Menzel, C; Panjideh, H; Petrausch, U; Thiel, E | 1 |
| Becker, PD; Camacho, EM; Cebolla, A; Guzmán, CA; Link, C; Royo, JL; Santero, E | 1 |
| Finlay, BB; Gal-Mor, O | 1 |
| Fujimori, M; Hamaji, Y; Hidaka, A; Sasaki, T; Taniguchi, S | 1 |
| Artemov, D; Bhujwalla, ZM; Li, C; Penet, MF; Winnard, P | 1 |
| Ardiani, A; Black, ME; Cundiff, J; Korkegian, AM; Stoddard, BL; Stolworthy, TS; Willmon, CL | 1 |
| Ascione, A; Barca, S; Cianfriglia, M; Dupuis, ML; Flego, M; Gellini, M; Mallano, A; Zamboni, S | 1 |
| Ghosh, SS; Gopinath, P | 1 |
| Akbulut, H; Akbulut, KG; Deisseroth, A; Maynard, J; Tang, Y | 1 |
| Beaulieu, C; Brzezinski, R; Clermont, N; Dubeau, MP; Ghinet, MG; Jacques, PE | 1 |
| Gao, FY; He, JQ; Huang, CJ; Lv, SQ; Yang, H; Yin, CL; Zhang, EE; Zhang, KB | 1 |
| Armeanu, S; Bitzer, M; Fuchs, J; Heigoldt, H; Heitmann, H; Lauer, UM; Lemken, ML; Ruck, P; Seitz, G; Vonthein, R; Warmann, SW | 1 |
| Duflot-Dancer, A; Mesnil, M; Piccoli, C; Tanaka, T; Tiraby, G; Tiraby, M; Yamasaki, H | 1 |
| Deng, X; Kotedia, K; Koutcher, JA; Li, GC; Ling, CC; Sun, X; Urano, M; Xing, L | 1 |
| Choi, S; Han, SU; Kim, DY; Kim, H; Kim, WJ; Kim, YM; Lee, G; Lee, SR; Shim, W; You, MH | 1 |
| Ebert, MO; Konrat, R; Kreutz, C; Micura, R; Puffer, B; Rieder, U | 1 |
| Altaner, C; Altanerova, V; Cavarretta, IT; Culig, Z; Kucerova, L; Matuskova, M | 1 |
| Cerullo, V; Diaconu, I; Dias, JD; Erbs, P; Eriksson, M; Escutenaire, S; Foloppe, J; Guse, K; Hakkarainen, T; Hemminki, A; Kanerva, A; Liikanen, I; Lusky, M; Pesonen, S; Rantanen, V; Sloniecka, M | 1 |
| Chang, DY; Cho, KG; Hong, Y; Kim, S; Kim, SJ; Kim, SS; Lee, YD; Paek, SH; Suh-Kim, H; Yoo, SW; Yoon, SH | 1 |
| Bouchara, JP; Brèthes, D; Chabasse, D; Larcher, G; Noel, T; Pineau, L; Vandeputte, P | 1 |
| Egerbacher, M; Günzburg, WH; Hlavaty, J; Jandl, G; König-Schuster, M; Liszt, M; Petznek, H; Renner, M; Salmons, B; Sedlak, J; Weissenberger, J | 1 |
| Artemov, D; Bhujwalla, ZM; Chen, Z; Li, C; Penet, MF; Takagi, T; Wildes, F; Winnard, PT | 1 |
| Goulet, ML; Hiscott, J; Leveille, S; Samuel, S | 1 |
| Harrison, RG; Van Rite, BD | 1 |
| Choi, KC; Heo, GJ; Hwang, KA; Jeung, EB; Kang, NH; Kim, SU; Kim, YB; O, SN; Yi, BR | 1 |
| Amundson, KK; Buckley, T; Burnett, R; Chen, CI; Daublebsky, V; Galvão da Silva, AP; Gruber, HE; Gunzburg, W; Hlavaty, J; Ibañez, CE; Jolly, DJ; Kasahara, N; Lin, AH; Lopez Espinoza, F; Martin, B; Ostertag, D; Perez, OD; Pettersson, PL; Robbins, JM; Valenta, DT | 1 |
| Bossow, S; Grossardt, C; Kalle, Cv; Leber, MF; Plinkert, PK; Springfeld, C; Ungerechts, G; Zaoui, K | 1 |
| Fuchs, BC; He, X; Kuroda, T; Lanuti, M; McGinn, CM; Schmitt, A; Supko, JG; Tanabe, KK; Yamada, S | 1 |
| Abe, M; Barresi, V; Hashimoto, O; Inoue, K; Iwamoto, H; Koga, H; Masuda, H; Nakamura, T; Nakashima, E; Sata, M; Taniguchi, E; Torimura, T; Ueno, T; Yano, H | 1 |
| Cho, MH; Choi, KC; Kim, SU; Kim, YB; Lee, HJ; Yi, BR | 1 |
| Amundson, K; Buckley, T; Burnett, R; Burrascano, C; Diago, O; Gruber, HE; Hiraoka, K; Ibanez, C; Inagaki, A; Jolly, DJ; Jolson, D; Kasahara, N; Lin, A; Logg, CR; Lohse, D; Perez, OD | 1 |
| Choi, KC; Choi, KJ; Kim, SU; Yi, BR | 1 |
| Chatzaki, E; Galaktidou, G; Goldberg, EP; Hohenforst-Schmidt, W; Karamanos, N; Kontakiotis, T; Zarogoulidis, K; Zarogoulidis, P | 1 |
| Choi, KC; Hwang, KA; Kim, SU; Kim, YB; Yi, BR | 1 |
| Amblard, F; Cho, JH; Coats, SJ; Schinazi, RF | 1 |
| Bragonzi, A; Facchini, M; Frangipani, E; Imperi, F; Leoni, L; Massai, F; Visaggio, D; Visca, P | 1 |
| Aboody, KS; Annala, AJ; Aramburo, S; Badie, B; Barish, ME; Blanchard, S; Brown, CE; Couture, LA; D'Apuzzo, M; Frank, RT; Garcia, E; Gutova, M; Kim, SU; Metz, MZ; Moats, RA; Najbauer, J; Portnow, J; Synold, TW; Valenzuela, VV | 1 |
| Bai, FL; Han, MM; Li, DS; Lu, Z; Ren, GP; Tian, GY; Wu, W; Zhang, TY | 1 |
| Choi, KC; Kim, DJ; Kim, SU; Lee, HR; Yi, BR | 1 |
| Joo, KM; Kang, W; Kim, J; Kim, SU; Kim, Y; Nam, DH; Seol, HJ; Seong, DH | 1 |
| Bai, FL; Chen, LQ; Li, DS; Lv, Z; Ren, GP; Sun, T; Wang, H; Wu, W; Yin, JC; Zhang, TY | 1 |
| Buckley, AF; Eisner, W; Sparks, MA; Spurney, RF; Tang, Y; Wang, L | 1 |
| Accoceberry, I; Brèthes, D; Dementhon, K; El-Kirat-Chatel, S; Fitton-Ouhabi, V; Gabriel, F; Noël, T; Pujol, S; Sabra, A | 1 |
| Berchtold, S; Bitzer, M; Lauer, UM; Malek, NP; Yurttas, C | 1 |
| Guillen, KP; Harrison, RG; Kurkjian, C; Restuccia, A | 1 |
| Choi, KC; Kim, SU; Yi, BR | 1 |
| Guo, FQ; Kang, L; Li, L; Wang, RF; Yan, P; Yin, L; Zhang, CL; Zhao, Q | 1 |
| Dadová, J; Hocek, M; Mačková, M; Olszewska, A | 1 |
| Abd-El-Barr, M; Aljuboori, Z; Anderson, JE; Chi, JH; Han, I; Haragopal, H; Kim, SU; Lee, HJ; Ropper, AE; Sidman, RL; Snyder, EY; Teng, YD; Viapiano, MS; Zeng, X | 1 |
| Bloomfield, S; Carter, B; Chen, CC; Chu, A; Cloughesy, TF; Das, A; Diago, OR; Elder, JB; Gammon, D; Gruber, HE; Hanna, M; Hogan, DJ; Jolly, DJ; Kalkanis, SN; Kasahara, N; Kesari, S; Lai, A; Landolfi, J; Lee, IY; Liau, LM; McCarthy, D; Mikkelsen, T; Mitchell, L; Nghiemphu, PL; Ostertag, D; Piccioni, D; Robbins, JM; Rodriguez-Aguirre, M; Vogelbaum, MA; Walbert, T | 1 |
| Egorov, VI; Grankina, EV; Kopantsev, EP; Kopantseva, MR; Kostina, MB; Sverdlov, ED | 1 |
| Alekseenko, IV; Bezborodova, OA; Boyko, AV; Gevorkov, AR; Khmelevskiy, EV; Kostina, MB; Monastyrskaya, GS; Nemtsova, ER; Sverdlov, ED; Venediktova, JB; Yakubovskaya, RI | 1 |
| Delord, JP; Erbs, P; Fournel-Federico, C; Guitton, J; Halluard, C; Homerin, M; Husseini, F; Jemming, C; Kurtz, JE; Limacher, JM; Orange, C | 1 |
| Huang, Z; Liu, Y; Shi, P; Zhou, L; Zhu, P | 1 |
| Accomando, W; Bloomfield, S; Carter, B; Chen, CC; Cloughesy, TF; Das, A; Diago, OR; Elder, JB; Gammon, D; Gruber, HE; Hogan, DJ; Jolly, DJ; Kalkanis, SN; Kasahara, N; Kesari, S; Kheoh, T; Lai, A; Landolfi, J; Lee, IY; Liau, LM; Mikkelsen, T; Nghiemphu, P; Ostertag, D; Piccioni, D; Vogelbaum, MA; Walbert, T | 1 |
| Das, A; Diago, OR; Gammon, D; Gruber, HE; Haghighi, A; Hogan, DJ; Jolly, DJ; Lu, G; Ostertag, D; Zhu, JJ | 1 |
| Altaner, C; Altanerova, U; Benejova, K; Jakubechova, J; Kausitz, J; Pesta, M; Pitule, P; Priscakova, P; Repiska, V; Topolcan, O; Zduriencikova, M | 1 |
| Carvalho, LA; de Melo Reis, RA; Fleming, RL; Tabet, EI; Tannous, BA; Teng, J; Zinter, M | 1 |
| Barcellos, VA; Fonseca, FL; Joffe, LS; Kmetzsch, L; Reuwsaat, JCV; Rodrigues, ML; Schrank, A; Staats, CC; Vainstein, MH; Zimbres, ACG | 1 |
| Berg, K; Hirschberg, H; Sun, CH | 1 |
| Darinskas, A; Kazlauskas, A; Meškys, R; Tamašauskas, A; Urbonavičius, J | 1 |
| Fiscarelli, EV; Imperi, F; Leoni, L; Visaggio, D; Visca, P | 1 |
| Bartoszewicz, M; Król, J; Nawrot, U | 1 |
| Berchtold, S; Lauer, UM; Maurer, S; Salih, HR; Smirnow, I | 1 |
| Beirne, JM; Brasino, M; Cha, JN; Chapnick, DA; Goodwin, AP; Harguindey, A; Liu, X; Roy, S | 1 |
| Montesdeoca-Esponda, S; Mordačíková, E; Santana-Rodríguez, JJ; Santana-Viera, S; Škvára, P; Vojs Staňová, A | 1 |
| Altaner, C; Altanerova, U; Babelova, A; Benejova, K; Jakubechova, J; Priscakova, P; Repiska, V; Smolkova, B | 1 |
| Beil, J; Berchtold, S; D'Alvise, J; Gross, S; Lauer, UM; Raff, C; Schell, M; Smirnow, I | 1 |
| Durinikova, E; Grabicová, K; Matuskova, M; Mordacikova, E; Skvara, P; Vojs Stanova, A | 1 |
| Béguin, J; Degorce, F; Erbs, P; Klonjkowski, B; Kohlhauer, M; Laloy, E; Maurey, C; Moreau, B; Quéméneur, É | 1 |
| Chao, Y; Chen, YY; Lan, KH; Lan, KL; Lee, TL; Pai, CW; Tsai, CL | 1 |
| Cha, JN; Corbella Bagot, C; Curry, SD; Goodwin, AP; Mansouri, AM; Mueller, EN; Park, W; Roy, S | 1 |
| Alcazar-Fuoli, L; Baldin, C; Dallemulle, A; Gsaller, F; Kühbacher, A; Müller, C; Niedrig, A; Sastré-Velásquez, LE | 1 |
| Altaner, C; Altanerova, U; Demkova, L; Furdova, A; Jakubechova, J; Klimova, D; Nicodemou, A; Smolkova, B; Zeleznikova, T | 1 |
| Bive, BZ; Bontems, S; Hayette, MP; Lelo, GM; Mudogo, CN; Sacheli, R; Zakayi, PK | 1 |
10 review(s) available for fluorouracil and flucytosine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Current dermatologic therapy.
Topics: Acne Vulgaris; Administration, Topical; Adrenal Cortex Hormones; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Agents; Betamethasone; Cryosurgery; Dermatomycoses; Flucytosine; Fluocinonide; Fluorouracil; Herpes Simplex; Humans; Keratosis; Levamisole; Propylene Glycols; Psoriasis; Pyoderma; Skin Diseases; Skin Neoplasms; Vitamin A; Warts | 1976 |
The cell cycle and the development of pathology in the gastrointestinal tract.
Topics: Adenine; Animals; Autoradiography; Cell Count; Cell Division; Colon; Digestive System; DNA; Flucytosine; Fluorouracil; Humans; Intestine, Small; Methotrexate; Pentosyltransferases; RNA; Stomach; Thymidine; Thymidine Kinase; Tritium | 1972 |
The pharmacology of the fluoropyrimidines.
Topics: Animals; Chemical Phenomena; Chemistry; Deoxyuracil Nucleotides; Flucytosine; Fluorodeoxyuridylate; Fluorouracil; Fungi; Humans; Kinetics; RNA; Thymidine; Thymidylate Synthase | 1981 |
The potential therapeutic gain of radiation-associated gene therapy with the suicide gene cytosine deaminase.
Topics: Animals; Antimetabolites; Cytosine Deaminase; Dose-Response Relationship, Drug; Flucytosine; Fluorouracil; Genetic Therapy; Humans; Mice; Models, Biological; Neoplasm Transplantation; Neoplasms; Nucleoside Deaminases; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 2000 |
Can neural stem cells be used to track down and destroy migratory brain tumor cells while also providing a means of repairing tumor-associated damage?
Topics: Animals; Brain Neoplasms; Cell Movement; Combined Modality Therapy; Cytosine Deaminase; Flucytosine; Fluorouracil; Glioblastoma; Hematopoietic Stem Cell Transplantation; Humans; Neurons; Nucleoside Deaminases; Prodrugs; Stem Cells | 2000 |
Fluorine nuclear magnetic resonance spectroscopy of human biofluids in the field of metabolic studies of anticancer and antifungal fluoropyrimidine drugs.
Topics: Antifungal Agents; Antimetabolites, Antineoplastic; Body Fluids; Flucytosine; Fluorine; Fluorouracil; Humans; Magnetic Resonance Spectroscopy | 2006 |
Interest of fluorine-19 nuclear magnetic resonance spectroscopy in the detection, identification and quantification of metabolites of anticancer and antifungal fluoropyrimidine drugs in human biofluids.
Topics: Antifungal Agents; Antimetabolites, Antineoplastic; Body Fluids; Flucytosine; Fluorine; Fluorouracil; Humans; Magnetic Resonance Spectroscopy | 2006 |
Therapeutic potential of stem cells expressing suicide genes that selectively target human breast cancer cells: evidence that they exert tumoricidal effects via tumor tropism (review).
Topics: Breast Neoplasms; Camptothecin; Cytosine Deaminase; Female; Flucytosine; Fluorouracil; Ganciclovir; Genes, Transgenic, Suicide; Genetic Engineering; Genetic Therapy; Humans; Irinotecan; Prodrugs; Stem Cells; Thymidine Kinase | 2012 |
Management of malignant pleural effusion by suicide gene therapy in advanced stage lung cancer: a case series and literature review.
Topics: Adenoviridae; Aged; Anemia; Animals; Antimetabolites, Antineoplastic; Bystander Effect; Carcinoma, Non-Small-Cell Lung; Cytosine Deaminase; Flucytosine; Fluorouracil; Genes, Transgenic, Suicide; Genetic Therapy; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neutropenia; Pleural Effusion, Malignant; Prodrugs; Proportional Hazards Models; Small Cell Lung Carcinoma; Tomography, X-Ray Computed | 2012 |
7 trial(s) available for fluorouracil and flucytosine
| Article | Year |
|---|---|
A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-
Topics: Acyltransferases; Antimetabolites; Antimetabolites, Antineoplastic; Combined Modality Therapy; Cytosine Deaminase; Dose-Response Relationship, Drug; Escherichia coli Proteins; Flucytosine; Fluorouracil; Gene Deletion; Gene Transfer Techniques; Humans; Lipid A; Maximum Tolerated Dose; Neoplasms; Nucleoside Deaminases; Salmonella typhimurium; Time Factors | 2001 |
5-fluorocytosine-related bone-marrow depression and conversion to fluorouracil: a pilot study.
Topics: Adult; Aged; beta-Alanine; Biotransformation; Bone Marrow; Candidiasis; Female; Flucytosine; Fluorouracil; Humans; Injections, Intravenous; Leukocyte Count; Leukopenia; Male; Meningitis, Cryptococcal; Middle Aged; Models, Theoretical; Pilot Projects; Platelet Count; Thrombocytopenia | 2002 |
Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients.
Topics: Aged; Aged, 80 and over; Cytosine Deaminase; Escherichia coli; Female; Flucytosine; Fluorouracil; Genetic Therapy; Head; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neck; Neoplasms; Pilot Projects; Salmonella | 2003 |
Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma.
Topics: Confidence Intervals; Cytosine Deaminase; Flucytosine; Fluorouracil; Genetic Vectors; Glioma; Prodrugs; Retroviridae; RNA, Messenger | 2016 |
Vectorized gene therapy of liver tumors: proof-of-concept of TG4023 (MVA-FCU1) in combination with flucytosine.
Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Cytosine Deaminase; Female; Flucytosine; Fluorouracil; Genetic Therapy; Genetic Vectors; Humans; Injections, Intralesional; Liver Neoplasms; Male; Middle Aged; Pentosyltransferases; Proof of Concept Study; Transgenes; Vaccinia virus | 2017 |
Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC.
Topics: Antimetabolites; Brain Neoplasms; Combined Modality Therapy; Cytosine Deaminase; Drug Synergism; Flucytosine; Fluorouracil; Follow-Up Studies; Genetic Vectors; Glioma; Humans; Prognosis; Retroviridae; Survival Rate | 2018 |
Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients.
Topics: Aged; Animals; Autopsy; Cell Line, Tumor; Cytosine Deaminase; Disease Models, Animal; Female; Flucytosine; Fluorouracil; Genetic Therapy; Genetic Vectors; Glioma; Humans; Male; Mice; Prodrugs; Retroviridae | 2018 |
202 other study(ies) available for fluorouracil and flucytosine
| Article | Year |
|---|---|
Antifungal properties of 2-bromo-3-fluorosuccinic acid esters and related compounds.
Topics: Antifungal Agents; Aspergillus niger; Candida albicans; Methods; Mucor; Structure-Activity Relationship; Succinates; Trichophyton | 1977 |
Anticandidal activity of 5-fluorocytosine-peptide conjugates.
Topics: Antifungal Agents; Candida; Cytosine; Drug Stability; Esters; Flucytosine; Hydrolysis; Microbial Sensitivity Tests; Oligopeptides; Saccharomyces cerevisiae | 1979 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
Topics: Amphotericin B; Antifungal Agents; Cryptococcus neoformans; DNA, Fungal; Drug Resistance, Fungal; Drug Synergism; Flucytosine; Fungal Proteins; Microbial Sensitivity Tests; Molecular Sequence Data; Sequence Analysis, DNA | 2007 |
Molecular mechanism of flucytosine resistance in Candida lusitaniae: contribution of the FCY2, FCY1, and FUR1 genes to 5-fluorouracil and fluconazole cross-resistance.
Topics: Alleles; Antifungal Agents; Candida; Cloning, Molecular; Cytosine Deaminase; DNA, Fungal; Drug Resistance, Fungal; Fluconazole; Flucytosine; Fluorouracil; Fungal Proteins; Genetic Complementation Test; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Pentosyltransferases; Plasmids; Sequence Analysis, DNA | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis.
Topics: Amino Acid Substitution; Antifungal Agents; Candida; Cytosine Deaminase; Drug Resistance, Fungal; Flucytosine; Microbial Sensitivity Tests; Tetracycline | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Inhibition of photo-induced Trichoderma viride conidiation by inhibitors of RNA synthesis.
Topics: Acridine Orange; Acriflavine; Azaguanine; Ethidium; Flucytosine; Fluorouracil; Hydroxyquinolines; Light; Mitosporic Fungi; Phenazines; RNA; Spores, Fungal; Trichoderma; Vidarabine; Virginiamycin | 1978 |
Studies on the mode of action of 5-fluorocytosine in Aspergillus species.
Topics: Aspergillus fumigatus; Aspergillus niger; Chromatography, Thin Layer; Cytosine; DNA; Drug Resistance, Microbial; Floxuridine; Flucytosine; Fluorouracil; Microbial Sensitivity Tests; Microbiological Techniques; RNA | 1979 |
Mutants of yeast specifically resistant to petite induction by fluorinated pyrimidines.
Topics: Cytosine; Drug Resistance, Microbial; Flucytosine; Fluorouracil; Phenotype; Saccharomyces cerevisiae; Selection, Genetic | 1977 |
The immunosuppressive effects of 5-fluorocytosine and 5-fluorouracil.
Topics: Animals; Antibody Formation; Concanavalin A; Cytosine; Female; Flucytosine; Fluorouracil; Humans; Immunosuppressive Agents; Lymphocyte Activation; Male; Mice; Phytohemagglutinins; Spleen | 1979 |
Studies on deamination of 5-fluorocytosine in fungal cells.
Topics: Cytosine; Deamination; Drug Resistance, Microbial; Flucytosine; Fluorouracil; Fungi; Species Specificity | 1979 |
Fluorinated pyrimidine nucleosides. 3. Synthesis and antitumor activity of a series of 5'-deoxy-5-fluoropyrimidine nucleosides.
Topics: Animals; Antineoplastic Agents; Flucytosine; Fluorouracil; Mice; Pyrimidine Nucleosides; Sarcoma 180; Structure-Activity Relationship | 1979 |
Evidence for conversion of 5-fluorocytosine to 5-fluorouracil in humans: possible factor in 5-fluorocytosine clinical toxicity.
Topics: Capsules; Cryptococcosis; Cytosine; Flucytosine; Fluorouracil; Humans; Kidney; Meningitis | 1978 |
The molecular events involved in the induction of petite yeast mutants by fluorinated pyrimidines.
Topics: Centrifugation, Isopycnic; Cytosine; DNA; Extrachromosomal Inheritance; Flucytosine; Fluorouracil; Genes; Mitochondria; Mutation; Saccharomyces cerevisiae | 1976 |
Nucleic acid related compounds. 21. Direct fluorination of uracil and cytosine bases and nucleosides using trifluoromethyl hypofluorite. Mechanism, stereochemistry, and synthetic applications.
Topics: Chlorofluorocarbons, Methane; Cytosine; Flucytosine; Fluorides; Fluorouracil; Hydrocarbons, Fluorinated; Indicators and Reagents; Methods; Nucleosides | 1976 |
Experimental and clinical studies on nucleoside analogs as antitumor agents.
Topics: Aged; Animals; Cytarabine; Drug Resistance; Flucytosine; Fluorouracil; Humans; Leukemia L1210; Leukemia, Experimental; Male; Methotrexate; Mice; Nasopharyngeal Neoplasms; Structure-Activity Relationship | 1975 |
Biological consequences of incorporation of 5-fluorocytidine in the RNA of 5-fluorouracil-treated eukaryotic cells.
Topics: Cytosine; Flucytosine; Fluorouracil; HeLa Cells; Mutation; RNA, Messenger; RNA, Viral; Structure-Activity Relationship; Templates, Genetic; Tobacco Mosaic Virus | 1976 |
[Diffuse chronic mucocutaneous candidiasis: Effects of antimycotics in vitro].
Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis, Cutaneous; Candidiasis, Oral; Child; Chronic Disease; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Female; Flucytosine; Fluorouracil; Humans; Hypersensitivity, Delayed; Immunologic Deficiency Syndromes; Immunotherapy; Lymphocyte Activation; Microbial Sensitivity Tests; Nystatin; Skin Diseases; Staphylococcal Infections | 1975 |
[Letter: A dangerous mistake--name confusion].
Topics: Adult; Female; Flucytosine; Fluorouracil; Humans; Medication Errors; Meningitis; Publishing; Terminology as Topic | 1976 |
Analysis of flucytosine dosage forms by derivative UV spectroscopy and liquid chromatography.
Topics: Chromatography, High Pressure Liquid; Dosage Forms; Flucytosine; Fluorouracil; Quality Control; Spectrophotometry, Ultraviolet | 1991 |
19F nuclear magnetic resonance study of fluoropyrimidine metabolism in strains of Candida glabrata with specific defects in pyrimidine metabolism.
Topics: Candida; Cells, Cultured; Cytosine Deaminase; Flucytosine; Fluorouracil; Magnetic Resonance Spectroscopy; Nucleoside Deaminases; Pentosyltransferases; Phenotype; RNA, Ribosomal; Uridine; Uridine Kinase | 1990 |
Effect of 5-fluorocytosine and 5-fluorouracil on human and rat hepatic cytochrome P 450.
Topics: Animals; Culture Techniques; Cytochrome P-450 Enzyme System; Flucytosine; Fluorouracil; Humans; Male; Microsomes, Liver; Rats; Rats, Inbred Strains | 1989 |
Selection of therapeutic agents for intraocular proliferative disease. II. Differing antiproliferative activity of the fluoropyrimidines.
Topics: Animals; Antineoplastic Agents; Cattle; Cell Division; Cell Line; Cells, Cultured; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Eye Neoplasms; Floxuridine; Flucytosine; Fluorouracil; Humans; Uridine | 1987 |
Isolation and characterization of fluoropyrimidine-resistant mutants in two Candida species.
Topics: Candida; Candida albicans; Drug Resistance, Microbial; Flucytosine; Fluorouracil; Mutation; Phenotype; Uridine | 1988 |
Determination of 5-fluorouracil in 5-fluorocytosine by high-performance thin-layer chromatography and derivative UV-spectrophotometry.
Topics: Chromatography, Thin Layer; Flucytosine; Fluorouracil; Spectrophotometry, Ultraviolet | 1988 |
Effect of 5-fluorocytosine in comparison with amphotericin B and/or 5-fluorouracil on the formation of human mature bursts/colonies of haemopoietic progenitor cells.
Topics: Amphotericin B; Cell Division; Cells, Cultured; Drug Interactions; Flucytosine; Fluorouracil; Hematopoietic Stem Cells; Humans | 1988 |
[Prediction of stability of flucytosine injections].
Topics: Drug Stability; Flucytosine; Fluorouracil; Hydrolysis; Injections | 1987 |
A 19F nuclear magnetic resonance study of uptake and metabolism of 5-fluorocytosine in susceptible and resistant strains of Candida albicans.
Topics: Candida albicans; Cytosine; Cytosine Deaminase; Drug Resistance, Microbial; Flucytosine; Fluorodeoxyuridylate; Fluorouracil; Magnetic Resonance Spectroscopy; Mutation; Nucleoside Deaminases; Pentosyltransferases | 1986 |
Treatment of a Zairian case of chromomycosis with oral 5-fluorocytosine and 5-fluorouracil ointment in association.
Topics: Aged; Chromoblastomycosis; Drug Combinations; Flucytosine; Fluorouracil; Humans; Male | 1987 |
Conversion of 5-fluorocytosine to 5-fluorouracil by human intestinal microflora.
Topics: Bacteria; Biotransformation; Chromatography, High Pressure Liquid; Cytosine; Feces; Fermentation; Flucytosine; Fluorouracil; Humans; Intestines; Spectrophotometry, Ultraviolet | 1986 |
Noninvasive and quantitative 19F nuclear magnetic resonance study of flucytosine metabolism in Candida strains.
Topics: Candida; Culture Media; Drug Resistance, Microbial; Flucytosine; Fluorouracil; Magnetic Resonance Spectroscopy; Pentosyltransferases; Uridine Triphosphate | 1986 |
[Monitoring of treatment involving 5-fluorocytosine].
Topics: Amphotericin B; Candidiasis; Cytosine; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Flucytosine; Fluorouracil; Humans; Kinetics | 1985 |
Antineoplastic effects in rats of 5-fluorocytosine in combination with cytosine deaminase capsules.
Topics: Animals; Brain Neoplasms; Capsules; Cytosine; Cytosine Deaminase; Drug Evaluation, Preclinical; Drug Therapy, Combination; Flucytosine; Fluorouracil; Glioma; Male; Nucleoside Deaminases; Passive Cutaneous Anaphylaxis; Rats; Rats, Inbred F344 | 1985 |
[Sensitivity and resistance of Candida to 5-fluorocytosine, 5-fluorouracil and 5-fluorouridine. Relation to the ecology and serotype of C. albicans].
Topics: Africa; Antifungal Agents; Candida; Candida albicans; Cytosine; Drug Resistance, Microbial; Europe; Flucytosine; Fluorouracil; Humans; Microbial Sensitivity Tests; Phenotype; Serotyping; Statistics as Topic; Uridine | 1974 |
[Study of radioactive 5-fluoropyrimidine incorporation in Candida. Mechanism of resistance to 5-fluorocytosine].
Topics: Antifungal Agents; Candida; Carbon Radioisotopes; Cells, Cultured; Cytosine; Drug Resistance, Microbial; Flucytosine; Fluorouracil; Humans; Membrane Transport Proteins; Microbial Sensitivity Tests; Mutation; Pyrimidines; Uracil | 1974 |
Metabolism of pyrimidines and pyrimidine nucleosides by Salmonella typhimurium.
Topics: Aminohydrolases; Cytidine; Cytosine; Deoxyuridine; Floxuridine; Flucytosine; Fluorouracil; Genetics, Microbial; Genotype; Mutation; Nucleosides; Nucleotidyltransferases; Pentosyltransferases; Phosphotransferases; Pyrimidines; Salmonella typhimurium; Thymidine; Uracil; Uracil Nucleotides; Uridine | 1972 |
Antimycotic therapy of experimental infections caused by dematiaceous fungi.
Topics: Amphotericin B; Animals; Antifungal Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Flucytosine; Fluorouracil; Humans; Ketoconazole; Male; Mice; Mitosporic Fungi; Mycoses; Triazoles | 1984 |
The effect of 5-fluorouracil and 5-fluorocytosine on the development of the filarial nematodes Brugia pahangi and Dirofilaria immitis.
Topics: Animals; Brugia; Cytosine; Dirofilaria immitis; Female; Filariasis; Filarioidea; Floxuridine; Flucytosine; Fluorouracil; Male; Microfilariae | 1981 |
Mode of action of 5-fluorocytosine and 5-fluorouracil in dematiaceous fungi.
Topics: Cytosine; Drug Resistance, Microbial; Floxuridine; Flucytosine; Fluorouracil; Mitosporic Fungi; RNA, Fungal; RNA, Ribosomal; Species Specificity; Uridine | 1983 |
[Induction of resistance of yeast-like fungi to synthetic antifungal agents].
Topics: Antifungal Agents; Candida; Clotrimazole; Culture Techniques; Drug Resistance, Microbial; Flucytosine; Fluorouracil; Miconazole; Uridine | 1983 |
In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine.
Topics: Adenoviridae; Animals; Antineoplastic Agents; beta-Galactosidase; Cell Division; Cell Line; Colonic Neoplasms; Cytosine Deaminase; Escherichia coli; Flucytosine; Fluorouracil; Gene Expression; Gene Transfer Techniques; Genetic Vectors; HT29 Cells; Humans; Mice; Mice, Nude; Nucleoside Deaminases; Prodrugs | 1995 |
Gene therapy for cancer using tumour-specific prodrug activation.
Topics: Base Sequence; Biotransformation; Breast Neoplasms; Cytosine Deaminase; DNA Primers; Female; Flucytosine; Fluorouracil; Genes, erbB-2; Genetic Therapy; Genetic Vectors; Humans; Molecular Sequence Data; Neoplasms; Nucleoside Deaminases; Pancreatic Neoplasms; Plasmids; Prodrugs; Retroviridae; Tumor Cells, Cultured | 1994 |
A conditional negative selection for Arabidopsis expressing a bacterial cytosine deaminase gene.
Topics: Acetyltransferases; Arabidopsis; Bacterial Proteins; Chimera; Cytosine Deaminase; DNA Primers; Escherichia coli Proteins; Flucytosine; Fluorouracil; Genetic Markers; Genetic Vectors; Molecular Sequence Data; Nucleoside Deaminases; Plants, Genetically Modified; Recombinant Proteins; Selection, Genetic | 1995 |
5-Fluoro-2-pyrimidinone, a liver aldehyde oxidase-activated prodrug of 5-fluorouracil.
Topics: Administration, Oral; Aldehyde Oxidase; Aldehyde Oxidoreductases; Animals; Biological Availability; Colonic Neoplasms; Flucytosine; Fluorouracil; Half-Life; Kinetics; Leukemia P388; Liver; Mice; Prodrugs | 1995 |
Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase.
Topics: Animals; Biotransformation; Cell Division; Cell Survival; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Cytosine Deaminase; DNA, Neoplasm; Flucytosine; Fluorouracil; Gene Expression; Humans; Kinetics; Mice; Mice, Nude; Nucleoside Deaminases; RNA, Neoplasm; Thymidylate Synthase; Time Factors; Transplantation, Heterologous; Tritium; Tumor Cells, Cultured | 1994 |
Intratumoral generation of 5-fluorouracil mediated by an antibody-cytosine deaminase conjugate in combination with 5-fluorocytosine.
Topics: Animals; Antibodies, Monoclonal; Cytosine Deaminase; Female; Flucytosine; Fluorouracil; Mice; Mice, Nude; Nucleoside Deaminases; Prodrugs; Tissue Distribution | 1994 |
Cytosine deaminase as a negative selective marker for Arabidopsis.
Topics: Arabidopsis; Biomarkers; Cytosine Deaminase; Escherichia coli Proteins; Flucytosine; Fluorouracil; Gene Expression; Nucleoside Deaminases; Plants, Genetically Modified; RNA, Messenger | 1993 |
In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase.
Topics: Animals; Cell Division; Colorectal Neoplasms; Cytosine Deaminase; Female; Flucytosine; Fluorouracil; Humans; Kinetics; Mice; Mice, Nude; Neoplasm Transplantation; Nucleoside Deaminases; Transfection; Transplantation, Heterologous; Tumor Cells, Cultured | 1993 |
A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing, and expression of Escherichia coli cytosine deaminase.
Topics: Amino Acid Sequence; Animals; Base Sequence; Cloning, Molecular; Colorectal Neoplasms; Cytosine Deaminase; DNA, Bacterial; Electrophoresis, Polyacrylamide Gel; Escherichia coli; Flucytosine; Fluorouracil; Genetic Therapy; Humans; Molecular Sequence Data; Mutagenesis, Site-Directed; Nucleoside Deaminases; Restriction Mapping; Tumor Cells, Cultured | 1993 |
Monitoring gene therapy with cytosine deaminase: in vitro studies using tritiated-5-fluorocytosine.
Topics: Chromatography, High Pressure Liquid; Cytosine Deaminase; Flucytosine; Fluorouracil; Genetic Therapy; Glioblastoma; Humans; In Vitro Techniques; Nucleoside Deaminases; Prodrugs; Tomography, Emission-Computed; Transfection; Tritium; Tumor Cells, Cultured | 1996 |
Cytosine deaminase gene as a potential tool for the genetic therapy of colorectal cancer.
Topics: Base Sequence; Cell Death; Cloning, Molecular; Colorectal Neoplasms; Cytosine Deaminase; Escherichia coli; Flucytosine; Fluorouracil; Genetic Therapy; Genetic Vectors; Glioblastoma; Humans; Interleukin-2; Molecular Sequence Data; Nucleoside Deaminases; Polymerase Chain Reaction; R Factors; Transfection; Tumor Cells, Cultured | 1996 |
Use of Epstein-Barr virus nuclear antigen-1 in targeted therapy of EBV-associated neoplasia.
Topics: Antigens, Viral; Base Sequence; Cell Survival; Cytosine Deaminase; DNA-Binding Proteins; Epstein-Barr Virus Nuclear Antigens; Flucytosine; Fluorouracil; Gene Expression Regulation; Gene Transfer Techniques; Genes, Reporter; Genetic Therapy; Genetic Vectors; Herpesvirus 4, Human; Humans; Luciferases; Molecular Sequence Data; Neoplasms; Nucleoside Deaminases; Prodrugs; Trans-Activators; Transfection; Tumor Cells, Cultured | 1996 |
Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia.
Topics: Animals; Antimetabolites, Antineoplastic; Base Sequence; Carcinoma; Cell Survival; Cloning, Molecular; Clostridium; Cytosine Deaminase; Escherichia coli; Flucytosine; Fluorouracil; Gene Transfer Techniques; Genetic Therapy; Mammary Neoplasms, Experimental; Mice; Molecular Sequence Data; Nucleoside Deaminases; Prodrugs; Transformation, Bacterial; Tumor Cells, Cultured | 1996 |
Tumor-specific gene expression in carcinoembryonic antigen--producing gastric cancer cells using adenovirus vectors.
Topics: Adenoviridae; Carcinoembryonic Antigen; Cytosine Deaminase; Flucytosine; Fluorouracil; Genetic Therapy; Genetic Vectors; Humans; Nucleoside Deaminases; Promoter Regions, Genetic; Stomach Neoplasms; Tumor Cells, Cultured | 1996 |
Expression of a reporter gene interrupted by the Candida albicans group I intron is inhibited by base analogs.
Topics: Antifungal Agents; beta-Galactosidase; Blotting, Northern; Blotting, Western; Candida albicans; Cell Division; Flucytosine; Fluorouracil; Gene Expression Regulation, Fungal; Genes, Reporter; Introns; Lac Operon; Mutagenesis, Site-Directed; Nucleic Acid Conformation; RNA Splicing; RNA, Ribosomal | 1997 |
Targeting gene expression to hypoxic tumor cells.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Hypoxia; Cytosine Deaminase; DNA-Binding Proteins; Fibrosarcoma; Flucytosine; Fluorouracil; Gene Expression Regulation, Neoplastic; Genes, Reporter; Humans; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Mice, Nude; Misonidazole; Neoplasm Transplantation; Nuclear Proteins; Nucleoside Deaminases; Oxygen; Phosphoglycerate Kinase; Prodrugs; Promoter Regions, Genetic; Recombinant Fusion Proteins; Transcription Factors; Tumor Cells, Cultured | 1997 |
Rapid and sensitive high-performance liquid chromatographic analysis of halogenopyrimidines in plasma.
Topics: 5-Methylcytosine; Antimetabolites, Antineoplastic; Bromouracil; Chromatography, High Pressure Liquid; Cytosine; Flucytosine; Fluorouracil; Humans; Hydrogen-Ion Concentration; Osmolar Concentration; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Uracil | 1997 |
Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cytosine Deaminase; Flucytosine; Fluorouracil; Ganciclovir; Genetic Therapy; Gliosarcoma; Humans; Mice; Mice, Nude; Mitosis; Nucleoside Deaminases; Phosphorylation; Prodrugs; Rats; Thymidine Kinase; Tumor Cells, Cultured | 1998 |
Regional 'pro-drug' gene therapy: intravenous administration of an adenoviral vector expressing the E. coli cytosine deaminase gene and systemic administration of 5-fluorocytosine suppresses growth of hepatic metastasis of colon carcinoma.
Topics: Adenoviridae; Animals; Antimetabolites; Colonic Neoplasms; Cytosine Deaminase; Escherichia coli; Flucytosine; Fluorouracil; Gene Expression; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Liver; Liver Neoplasms; Mice; Mice, Inbred BALB C; Nucleoside Deaminases; Prodrugs | 1998 |
Selective in vivo radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells transduced with the E. coli cytosine deaminase (CD) gene.
Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Cytosine Deaminase; Escherichia coli; Female; Flucytosine; Fluorouracil; Genetic Therapy; Genetic Vectors; Humans; Mice; Mice, Inbred Strains; Mice, Nude; Nucleoside Deaminases; Prodrugs; Radiation-Sensitizing Agents; Radiotherapy Dosage | 1998 |
Cytosine deaminase adenoviral vector and 5-fluorocytosine selectively reduce breast cancer cells 1 million-fold when they contaminate hematopoietic cells: a potential purging method for autologous transplantation.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Death; Cytosine Deaminase; Female; Flucytosine; Fluorouracil; Gene Transfer Techniques; Genetic Vectors; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Male; Mice; Nucleoside Deaminases; Prodrugs; Transplantation, Autologous; Tumor Cells, Cultured | 1998 |
Intratumoral conversion of 5-fluorocytosine to 5-fluorouracil by monoclonal antibody-cytosine deaminase conjugates: noninvasive detection of prodrug activation by magnetic resonance spectroscopy and spectroscopic imaging.
Topics: Animals; Female; Flucytosine; Fluorine; Fluorouracil; Humans; Magnetic Resonance Spectroscopy; Mice; Prodrugs | 1998 |
[Experimental treatment of brain tumor cells using CD suicide gene].
Topics: Animals; Antimetabolites, Antineoplastic; Brain Neoplasms; Cytosine Deaminase; Escherichia coli; Flucytosine; Fluorouracil; Genes; Genetic Therapy; Glioma; Nucleoside Deaminases; Rats; Retroviridae; Transfection; Tumor Cells, Cultured | 1996 |
Concomitant expression of E. coli cytosine deaminase and uracil phosphoribosyltransferase improves the cytotoxicity of 5-fluorocytosine.
Topics: Animals; Antimetabolites, Antineoplastic; Artificial Gene Fusion; Cytosine Deaminase; Drug Resistance; Escherichia coli; Escherichia coli Proteins; Flucytosine; Fluorouracil; Gene Expression; Genes, Bacterial; Mutation; Neoplasms, Experimental; Nucleoside Deaminases; Pentosyltransferases; Prodrugs | 1998 |
Ex vivo breast cancer cell purging by adenovirus-mediated cytosine deaminase gene transfer and short-term incubation with 5-fluorocytosine completely prevents tumor growth after transplantation.
Topics: Adenoviridae; Animals; Antigens, CD34; Breast Neoplasms; Cytosine Deaminase; Female; Flucytosine; Fluorouracil; Gene Transfer Techniques; Genetic Vectors; Hematopoietic Stem Cells; Humans; Mice; Mice, SCID; Neoplasm Transplantation; Nucleoside Deaminases; Prodrugs; Tumor Cells, Cultured | 1998 |
Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts.
Topics: Animals; Bacteria; Colonic Neoplasms; Cytosine Deaminase; Female; Flucytosine; Fluorouracil; Genetic Therapy; Humans; Mice; Neoplasm Transplantation; Nucleoside Deaminases; Prodrugs; Transplantation, Heterologous; Tumor Cells, Cultured; Yeasts | 1999 |
An accelerated stability study of 5-flucytosine in intravenous solution.
Topics: Antifungal Agents; Chromatography, High Pressure Liquid; Drug Stability; Flucytosine; Fluorouracil; Infusions, Intravenous; Pharmaceutical Solutions; Spectrophotometry, Ultraviolet; Time Factors | 1999 |
Cytosine deaminase/5-fluorocytosine gene therapy can induce efficient anti-tumor effects and protective immunity in immunocompetent mice but not in athymic nude mice.
Topics: Animals; Cytosine Deaminase; Flucytosine; Fluorouracil; Genetic Therapy; Genetic Vectors; Liver Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Nucleoside Deaminases; Retroviridae; Time Factors | 1999 |
Noninvasive quantitation of cytosine deaminase transgene expression in human tumor xenografts with in vivo magnetic resonance spectroscopy.
Topics: Animals; Catalysis; Cytosine Deaminase; Flucytosine; Fluorouracil; Gene Expression Regulation, Enzymologic; Humans; Kinetics; Magnetic Resonance Imaging; Mice; Nucleoside Deaminases; Transgenes; Transplantation, Heterologous; Tumor Cells, Cultured | 1999 |
Enzyme/prodrug-based tumor vaccination: all politics (and immunity) are local.
Topics: Animals; Antifungal Agents; Antimetabolites; Antineoplastic Agents; Biotransformation; Cancer Vaccines; Cytosine Deaminase; Escherichia coli; Flucytosine; Fluorouracil; Genetic Therapy; Nucleoside Deaminases; Prodrugs; Transfection | 1999 |
Cytosine deaminase/5-fluorocytosine-based vaccination against liver tumors: evidence of distant bystander effect.
Topics: Animals; Antifungal Agents; Antimetabolites; Antineoplastic Agents; Cancer Vaccines; Colonic Neoplasms; Cytosine Deaminase; Escherichia coli; Flow Cytometry; Flucytosine; Fluorouracil; Genetic Therapy; Killer Cells, Natural; Liver Neoplasms; Male; Nucleoside Deaminases; Rats; Transfection; Tumor Cells, Cultured | 1999 |
Construction and testing of gene therapy retroviral vector expressing bacterial cytosine deaminase gene.
Topics: Animals; Cell Line; Cytosine Deaminase; Flucytosine; Fluorouracil; Genetic Therapy; Genetic Vectors; Humans; Leucovorin; Mice; Nucleoside Deaminases; Retroviridae | 1999 |
Breast cancer-specific expression of the Candida albicans cytosine deaminase gene using a transcriptional targeting approach.
Topics: Adenoviridae; Animals; Breast Neoplasms; Candida albicans; Carrier Proteins; Cell Survival; Cytosine Deaminase; Female; Flucytosine; Fluorouracil; Gene Expression; Gene Targeting; Genetic Therapy; Genetic Vectors; Humans; Lactalbumin; Lactoglobulins; Mice; Mice, Inbred BALB C; Mice, Nude; Nucleoside Deaminases; Prodrugs; Receptors, Estrogen; Transcriptional Activation; Tumor Cells, Cultured | 2000 |
Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Cytosine Deaminase; Dose-Response Relationship, Drug; Drug Interactions; Flucytosine; Fluorouracil; Genetic Therapy; Mice; Mice, Inbred C57BL; Mice, Nude; Nucleoside Deaminases; Prodrugs; Tumor Cells, Cultured; Vaccinia virus; Virus Replication | 2000 |
Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer.
Topics: Antigens, Surface; Base Sequence; Carboxypeptidases; Cell Division; Cytosine Deaminase; DNA, Complementary; Enhancer Elements, Genetic; Escherichia coli; Flucytosine; Fluorouracil; Genes, Reporter; Genetic Therapy; Glutamate Carboxypeptidase II; Green Fluorescent Proteins; Humans; Luminescent Proteins; Male; Molecular Sequence Data; Nucleoside Deaminases; Prodrugs; Promoter Regions, Genetic; Transfection; Tumor Cells, Cultured | 2000 |
Yeast cytosine deaminase improves radiosensitization and bystander effect by 5-fluorocytosine of human colorectal cancer xenografts.
Topics: Animals; Antimetabolites, Antineoplastic; Bacteria; Biotransformation; Cytosine Deaminase; Female; Flucytosine; Fluorouracil; Genetic Therapy; HT29 Cells; Humans; Mice; Mice, Nude; Nucleoside Deaminases; Prodrugs; Radiation-Sensitizing Agents; Saccharomyces cerevisiae; Transduction, Genetic; Xenograft Model Antitumor Assays | 2000 |
Usefulness of repeated direct intratumoral gene transfer using hemagglutinating virus of Japan-liposome method for cytosine deaminase suicide gene therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Division; Cytosine Deaminase; Feasibility Studies; Female; Flucytosine; Fluorouracil; Genetic Therapy; Genetic Vectors; Humans; Injections, Intralesional; Liposomes; Mice; Mice, Inbred BALB C; Mice, Nude; Nucleoside Deaminases; Pancreatic Neoplasms; Respirovirus; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transfection; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
Simultaneous determination of flucytosine and fluorouracil in human plasma by high-performance liquid chromatography.
Topics: Calibration; Chromatography, High Pressure Liquid; Flucytosine; Fluorouracil; Humans; Reference Standards; Reproducibility of Results; Sensitivity and Specificity | 2001 |
Hydrophilic interaction chromatography using amino and silica columns for the determination of polar pharmaceuticals and impurities.
Topics: Acetamides; Acyclovir; Amines; Chromatography, High Pressure Liquid; Chromatography, Ion Exchange; Flucytosine; Fluorouracil; Guanine; Molecular Weight; Pharmaceutical Preparations; Sensitivity and Specificity; Silicon Dioxide | 2001 |
The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines.
Topics: Adenoviridae; Animals; Cytomegalovirus; Cytosine Deaminase; Female; Flucytosine; Fluorouracil; Gene Expression; Genetic Therapy; Genetic Vectors; Humans; Inhibitory Concentration 50; Lac Operon; Membrane Glycoproteins; Mice; Mice, Nude; Microfilament Proteins; Nucleoside Deaminases; Ovarian Neoplasms; Phosphoproteins; Promoter Regions, Genetic; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2001 |
Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum.
Topics: Animals; Antifungal Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Clostridium; Cytosine Deaminase; DNA Primers; Drug Delivery Systems; Escherichia coli; Flucytosine; Fluorouracil; Genetic Therapy; Genetic Vectors; In Vitro Techniques; Neoplasm Transplantation; Nucleoside Deaminases; Plasmids; Rats; Recombinant Proteins; Rhabdomyosarcoma; Skin Neoplasms; Stilbenes | 2001 |
Stereospecific synthesis and biological evaluations of beta-L-pentofuranonucleoside derivatives of 5-fluorouracil and 5-fluorocytosine.
Topics: Animals; Anti-HIV Agents; Antineoplastic Agents; Cell Division; Drug Design; Flucytosine; Fluorouracil; HIV; Humans; Mice; Nucleosides; Stereoisomerism; Structure-Activity Relationship; T-Lymphocytes; Tumor Cells, Cultured | 2001 |
Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil.
Topics: Animals; Chlorocebus aethiops; Combined Modality Therapy; Cytosine Deaminase; Flucytosine; Fluorouracil; Genetic Therapy; Genetic Vectors; Herpesvirus 1, Human; HT29 Cells; Humans; Mice; Mice, Inbred BALB C; Mutation; Neoplasms, Experimental; Nucleoside Deaminases; Prodrugs; Saccharomyces cerevisiae; Survival Analysis; Vero Cells; Virus Replication | 2001 |
In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase.
Topics: Adenoviridae; Analysis of Variance; Animals; Artificial Gene Fusion; Bystander Effect; Colonic Neoplasms; Cytosine Deaminase; Flucytosine; Fluorouracil; Genetic Therapy; Genetic Vectors; Humans; Injections, Intralesional; Mice; Mice, Nude; Neoplasm Transplantation; Nucleoside Deaminases; Pentosyltransferases; Prodrugs; Random Allocation; Transfection; Transplantation, Heterologous; Tumor Cells, Cultured | 2001 |
Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Brain Neoplasms; Cytosine Deaminase; Flucytosine; Fluorouracil; Genetic Therapy; Genetic Vectors; Glioblastoma; Humans; Injections, Intralesional; Mice; Mice, SCID; Nucleoside Deaminases; Prodrugs; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
Subcutaneous or intrahepatic injection of suicide gene modified tumour cells induces a systemic antitumour response in a metastatic model of colon carcinoma in rats.
Topics: Animals; Antimetabolites, Antineoplastic; Bystander Effect; Colonic Neoplasms; Cytosine Deaminase; Disease Models, Animal; Flucytosine; Fluorouracil; Genetic Therapy; Injections, Intralesional; Injections, Subcutaneous; Liver Neoplasms; Male; Neoplasm Transplantation; Nucleoside Deaminases; Prodrugs; Rats; Tumor Cells, Cultured | 2002 |
Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis.
Topics: Animals; Carcinoma, Squamous Cell; Cell Hypoxia; Clostridium; Cytosine Deaminase; Flucytosine; Fluorouracil; Gene Targeting; Genetic Therapy; Genetic Vectors; Mice; Mice, Inbred C3H; Necrosis; Neoplasm Transplantation; Nucleoside Deaminases; Prodrugs | 2002 |
SDT1/SSM1, a multicopy suppressor of S-II null mutant, encodes a novel pyrimidine 5'-nucleotidase.
Topics: 5'-Nucleotidase; Amphotericin B; Antifungal Agents; Dose-Response Relationship, Drug; Escherichia coli; Fluconazole; Flucytosine; Fluorouracil; Fungal Proteins; Molecular Sequence Data; Nucleotidases; Phosphorylation; Protein Binding; Recombinant Proteins; Ribosomal Proteins; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Substrate Specificity | 2002 |
A new delivery system for 5-fluorouracil using prodrug and converting enzyme.
Topics: Animals; Antimetabolites; Cell Division; Cells, Cultured; Cytosine Deaminase; DNA; Drug Delivery Systems; Fibroblasts; Flucytosine; Fluorouracil; Nucleoside Deaminases; Prodrugs; Rabbits | 2002 |
Naked DNA injection for liver metastases treatment in rats.
Topics: Animals; Antimetabolites; Colonic Neoplasms; Cytosine Deaminase; Disease Models, Animal; Flucytosine; Fluorouracil; Gene Transfer Techniques; Genetic Therapy; Hepatectomy; Killer Cells, Natural; Liver Neoplasms, Experimental; Male; Neoplasm Transplantation; Nucleoside Deaminases; Plasmids; Rats; Rats, Inbred Strains; Survival Rate; Tumor Cells, Cultured | 2002 |
Tumor-targeted Salmonella expressing cytosine deaminase as an anticancer agent.
Topics: Animals; Antineoplastic Agents; Biotransformation; Colonic Neoplasms; Cytosine Deaminase; Escherichia coli; Female; Flucytosine; Fluorouracil; Genetic Markers; Humans; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Nucleoside Deaminases; Organ Specificity; Salmonella typhimurium; Tumor Cells, Cultured | 2002 |
Enzyme-activated Prodrug Therapy Enhances Tumor-specific Replication of Adenovirus Vectors.
Topics: Adenoviridae; Biotransformation; Camptothecin; Cell Cycle; Combined Modality Therapy; Cytopathogenic Effect, Viral; Cytosine Deaminase; DNA Replication; Flucytosine; Fluorouracil; Genetic Therapy; Glucuronidase; Glucuronides; HeLa Cells; Humans; Nucleoside Deaminases; Pentosyltransferases; Prodrugs; Transgenes; Virus Replication | 2002 |
Cytosine deaminase and thymidine kinase gene therapy in a Dunning rat prostate tumour model: absence of bystander effects and characterisation of 5-fluorocytosine metabolism with 19F-NMR spectroscopy.
Topics: Animals; Antimetabolites; Bystander Effect; Cell Survival; Cytosine Deaminase; Disease Models, Animal; Disease-Free Survival; Flucytosine; Fluorouracil; Genetic Therapy; Magnetic Resonance Spectroscopy; Male; Nucleoside Deaminases; Prodrugs; Prostatic Neoplasms; Rats; Recombinant Fusion Proteins; Thymidine Kinase; Transfection; Tumor Cells, Cultured | 2002 |
Adenovirus mediated prostate specific enzyme prodrug gene therapy using prostate specific antigen promoter enhanced by the Cre-loxP system.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Cytosine Deaminase; Enhancer Elements, Genetic; Flucytosine; Fluorouracil; Genetic Therapy; Genetic Vectors; Humans; Integrases; Luciferases; Male; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Nucleoside Deaminases; Plasmids; Prodrugs; Promoter Regions, Genetic; Prostate-Specific Antigen; Prostatic Neoplasms; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Viral Proteins | 2002 |
Potential benefits of combining cytosine deaminase/5-fluorocytosine gene therapy and irradiation for prostate cancer: experimental study.
Topics: Animals; Antimetabolites; Combined Modality Therapy; Cytosine Deaminase; Flucytosine; Fluorouracil; Genetic Therapy; Humans; Male; Mice; Mice, SCID; Models, Animal; Nucleoside Deaminases; Prostatic Neoplasms; Radioimmunotherapy; Radiotherapy; Tumor Cells, Cultured | 2002 |
Cloned cytosine deaminase gene expression of Bifidobacterium longum and application to enzyme/pro-drug therapy of hypoxic solid tumors.
Topics: Antimetabolites, Antineoplastic; Bifidobacterium; Blotting, Western; Cloning, Molecular; Cytosine Deaminase; Flucytosine; Fluorouracil; Gene Expression; Genetic Therapy; Genetic Vectors; Hypoxia; Neoplasms; Nucleoside Deaminases; Prodrugs; Transfection; Transformation, Bacterial | 2002 |
Regional delivery and selective expression of a high-activity yeast cytosine deaminase in an intrahepatic colon cancer model.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Carcinoembryonic Antigen; Colonic Neoplasms; Cytosine Deaminase; Flucytosine; Fluorouracil; Gene Expression; Genetic Therapy; Genetic Vectors; Humans; Immunoblotting; Liver Neoplasms; Nucleoside Deaminases; Prodrugs; Promoter Regions, Genetic; Rats; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2003 |
Crystal structure of yeast cytosine deaminase. Insights into enzyme mechanism and evolution.
Topics: Amino Acid Sequence; Antineoplastic Agents; Binding Sites; Catalysis; Crystallization; Cytosine Deaminase; Dimerization; Enzyme Inhibitors; Escherichia coli; Evolution, Molecular; Flucytosine; Fluorouracil; Hydrogen Bonding; Models, Molecular; Molecular Sequence Data; Molecular Structure; Nucleoside Deaminases; Pyrimidines; Saccharomyces cerevisiae; Sequence Alignment; Stereoisomerism; Substrate Specificity | 2003 |
An in vitro study on the active conversion of flucytosine to fluorouracil by microorganisms in the human intestinal microflora.
Topics: Antifungal Agents; Child; Dose-Response Relationship, Drug; Escherichia coli; Feces; Female; Flucytosine; Fluorouracil; Humans; Intestines; Male; Middle Aged; Neutropenia | 2003 |
Transplantation of prodrug-converting neural progenitor cells for brain tumor therapy.
Topics: Animals; Brain Neoplasms; Cells, Cultured; Cytosine Deaminase; Escherichia coli; Flucytosine; Fluorouracil; Genetic Therapy; Glioma; Neurons; Prodrugs; Rats; Rats, Sprague-Dawley; Stem Cell Transplantation; Stem Cells; Transfection | 2003 |
Effects of CD/5-FC suicide gene therapy system on human malignant glioma cells in vitro.
Topics: Cell Death; Cell Division; Culture Media; Cytosine Deaminase; Flucytosine; Fluorouracil; Genetic Therapy; Genetic Vectors; Glioma; Humans; Nucleoside Deaminases; Transfection; Tumor Cells, Cultured | 2003 |
Direct and bystander killing of sarcomas by novel cytosine deaminase fusion gene.
Topics: Animals; Bone Neoplasms; Cell Line, Tumor; Cytosine Deaminase; Flucytosine; Fluorouracil; Genetic Therapy; Mice; Mice, Inbred C3H; Osteosarcoma; Receptors, Nerve Growth Factor; Recombinant Fusion Proteins; Sarcoma | 2003 |
Non-invasive 19F MR spectroscopy of 5-fluorocytosine to 5-fluorouracil conversion by recombinant Salmonella in tumours.
Topics: Animals; Cytosine Deaminase; Flucytosine; Fluorine Radioisotopes; Fluorouracil; HCT116 Cells; Humans; Injections, Intralesional; Injections, Intraperitoneal; Injections, Intravenous; Liver; Magnetic Resonance Spectroscopy; Neoplasm Transplantation; Prodrugs; Salmonella typhimurium; Transplants; Xenograft Model Antitumor Assays | 2003 |
The oncolytic effect of recombinant vesicular stomatitis virus is enhanced by expression of the fusion cytosine deaminase/uracil phosphoribosyltransferase suicide gene.
Topics: Animals; Cell Line, Tumor; Cytosine Deaminase; Escherichia coli; Flucytosine; Fluorouracil; Genetic Therapy; Genetic Vectors; Humans; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Pentosyltransferases; Prodrugs; Recombinant Fusion Proteins; Vesicular stomatitis Indiana virus; Virus Replication | 2003 |
Insect population control using female specific pro-drug activation.
Topics: Animals; Animals, Genetically Modified; Cytosine Deaminase; DNA Transposable Elements; Drosophila melanogaster; Escherichia coli; Female; Flucytosine; Fluorouracil; Genes, Insect; Homozygote; Infertility, Female; Male; Pest Control, Biological; Prodrugs; Promoter Regions, Genetic | 2004 |
Recombinant adenoviral vector containing tumor-specific L-plastin promoter fused to cytosine deaminase gene as a transcription unit: generation and functional test.
Topics: Adenoviridae; Artificial Gene Fusion; Cell Line, Tumor; Chromatography, High Pressure Liquid; Cytosine Deaminase; Female; Flucytosine; Fluorouracil; Gene Transfer Techniques; Genetic Vectors; Humans; Membrane Glycoproteins; Microfilament Proteins; Ovarian Neoplasms; Phosphoproteins; Polymerase Chain Reaction; Promoter Regions, Genetic | 2004 |
Molecular mechanisms of primary resistance to flucytosine in Candida albicans.
Topics: Amino Acid Sequence; Antifungal Agents; Antimetabolites; Candida albicans; Cytosine Deaminase; DNA Primers; DNA, Fungal; Drug Resistance, Fungal; Flucytosine; Fluorouracil; Genes, Fungal; Membrane Transport Proteins; Microbial Sensitivity Tests; Models, Molecular; Molecular Sequence Data; Nucleobase Transport Proteins; Pentosyltransferases; Polymorphism, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Saccharomyces cerevisiae Proteins | 2004 |
The use of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies.
Topics: Animals; Antineoplastic Agents; Artificial Gene Fusion; Brain; Cytosine Deaminase; Diffusion Magnetic Resonance Imaging; Flucytosine; Fluorine; Fluorodeoxyuridylate; Fluorouracil; Gene Expression; Genetic Therapy; Magnetic Resonance Spectroscopy; Neoplasms; Optic Nerve Glioma; Pentosyltransferases; Prodrugs; Rats; Transduction, Genetic | 2004 |
Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization.
Topics: Adenoviridae; Adenovirus E1A Proteins; Base Sequence; Blotting, Western; Cell Line, Tumor; Chromatography, Thin Layer; Cytosine Deaminase; DNA Primers; Flucytosine; Fluorouracil; Genetic Therapy; Genetic Vectors; Glioma; Humans; Immunohistochemistry; Inhibitory Concentration 50; Molecular Sequence Data; Mutation; Reverse Transcriptase Polymerase Chain Reaction; Saccharomyces cerevisiae; Transplantation, Heterologous; Viruses | 2005 |
Development of a hypoxia-inducible cytosine deaminase expression vector for gene-directed prodrug cancer therapy.
Topics: Blotting, Western; Cell Hypoxia; Cell Line, Tumor; Cytosine Deaminase; Enhancer Elements, Genetic; Erythropoietin; Flucytosine; Fluorouracil; Genetic Therapy; Genetic Vectors; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Neoplasms; Prodrugs; Simian virus 40; Transcription Factors; Transfection; Tumor Stem Cell Assay; Yeasts | 2005 |
Product release is rate-limiting in the activation of the prodrug 5-fluorocytosine by yeast cytosine deaminase.
Topics: Antimetabolites, Antineoplastic; Base Sequence; Cytosine Deaminase; DNA, Fungal; Flucytosine; Fluorouracil; Humans; In Vitro Techniques; Kinetics; Mutagenesis, Site-Directed; Nuclear Magnetic Resonance, Biomolecular; Prodrugs; Recombinant Proteins; Saccharomyces cerevisiae | 2005 |
Osteoclasts direct bystander killing of cancer cells in vitro.
Topics: Animals; Antimetabolites, Antineoplastic; Bone Marrow Cells; Bone Neoplasms; Breast Neoplasms; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Coculture Techniques; Cytosine Deaminase; Flow Cytometry; Flucytosine; Fluorouracil; Green Fluorescent Proteins; Humans; Immunohistochemistry; Macrophages; Mice; NIH 3T3 Cells; Osteoclasts; Receptor, Nerve Growth Factor; Recombinant Fusion Proteins; Retroviridae; Saccharomyces cerevisiae; Sarcoma; Transduction, Genetic | 2006 |
[Effects of CD/5-FC suicide gene therapy system on human malignant glioma cells in vitro].
Topics: Brain Neoplasms; Cytosine Deaminase; Flucytosine; Fluorouracil; Gene Transfer Techniques; Genetic Therapy; Glioma; Humans; Transfection; Tumor Cells, Cultured | 2004 |
Advances in radiosensitization.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Drug Delivery Systems; Flucytosine; Fluorouracil; Gefitinib; Humans; Neoplasm Proteins; Neoplasms; Prodrugs; Protein Kinase Inhibitors; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Trastuzumab | 2004 |
Fusion of the HSV-1 tegument protein vp22 to cytosine deaminase confers enhanced bystander effect and increased therapeutic benefit.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Bystander Effect; Cell Line; Cytosine Deaminase; Flucytosine; Fluorouracil; Gene Fusion; Genetic Engineering; Genetic Therapy; Humans; Immunohistochemistry; Magnetic Resonance Spectroscopy; Male; Mice; Mice, Nude; Saccharomyces cerevisiae; Transduction, Genetic; Translocation, Genetic; Viral Structural Proteins | 2006 |
Predicting toxicity during 5-fluorocytosine (5-FC) therapy by plasma level monitoring: a lesson to learn from cytostatic 5-fluorouracil (5 FU) pro-drugs.
Topics: Antimetabolites; Floxuridine; Flucytosine; Fluorouracil; Humans; Metabolic Clearance Rate; Monitoring, Physiologic; Prodrugs | 1989 |
A novel mechanism of synergistic cytotoxicity with 5-fluorocytosine and ganciclovir in double suicide gene therapy.
Topics: Adenoviridae; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cytosine Deaminase; Deoxyguanosine; Deoxyribonucleotides; Drug Administration Schedule; Drug Synergism; Flucytosine; Fluorouracil; Ganciclovir; Genetic Therapy; Genetic Vectors; Humans; Male; Prostatic Neoplasms; Simplexvirus; Thymidine Kinase | 2006 |
Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control.
Topics: Animals; Biotransformation; Cell Fusion; Combined Modality Therapy; Cytosine Deaminase; Fibrosarcoma; Flucytosine; Fluorouracil; Humans; Leukemia Virus, Gibbon Ape; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Oncolytic Virotherapy; Pentosyltransferases; Prodrugs; Rats; Recombinant Fusion Proteins; Simplexvirus; Virus Replication; Xenograft Model Antitumor Assays | 2006 |
Cytosine deaminase producing Clostridium may be used in detection of tumors.
Topics: Bacterial Proteins; Clostridium; Cytosine Deaminase; Flucytosine; Fluorouracil; Humans; Neoplasms | 2006 |
Efficacy of gene therapy-delivered cytosine deaminase is determined by enzymatic activity but not expression.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Chromatography, Thin Layer; Cytosine Deaminase; Female; Flucytosine; Fluorouracil; Genetic Therapy; Genetic Vectors; Humans; Magnetic Resonance Spectroscopy; Mice; Neoplasms, Experimental; Prodrugs; Salmonella typhimurium; Xenograft Model Antitumor Assays | 2007 |
Improvement of antitumor activity by gene amplification with a replicating but nondisseminating adenovirus.
Topics: Adenoviridae; Animals; Cell Line, Tumor; Cytosine Deaminase; Flucytosine; Fluorouracil; Gene Amplification; Genetic Therapy; Genetic Vectors; Genome, Viral; Glioblastoma; Humans; Mice; Mice, Inbred C57BL; Mice, Nude; Pentosyltransferases; Peptide Hydrolases; Spheroids, Cellular; Transgenes; Virus Replication | 2007 |
Strong enhancement of recombinant cytosine deaminase activity in Bifidobacterium longum for tumor-targeting enzyme/prodrug therapy.
Topics: Antimetabolites; Antineoplastic Agents; Bifidobacterium; Binding Sites; Blotting, Western; Chromatography, High Pressure Liquid; Cytosine Deaminase; Flucytosine; Fluorouracil; Mutation; Plasmids; Prodrugs; Recombinant Proteins | 2007 |
Therapeutic efficacy of replication-competent retrovirus vector-mediated suicide gene therapy in a multifocal colorectal cancer metastasis model.
Topics: Animals; Colorectal Neoplasms; Cytosine Deaminase; Disease Models, Animal; Female; Flucytosine; Fluorouracil; Genes, Transgenic, Suicide; Genetic Therapy; Genetic Vectors; Humans; Liver Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Retroviridae; Virus Replication | 2007 |
Design, construction, and in vitro analysis of A33scFv::CDy, a recombinant fusion protein for antibody-directed enzyme prodrug therapy in colon cancer.
Topics: Antibodies, Monoclonal; Antibody Specificity; Artificial Gene Fusion; Chromatography, Affinity; Cloning, Molecular; Colonic Neoplasms; Cytosine Deaminase; Flow Cytometry; Flucytosine; Fluorouracil; Humans; Immunoglobulin Fragments; Membrane Glycoproteins; Pichia; Prodrugs; Protein Engineering; Recombinant Fusion Proteins; Tumor Cells, Cultured | 2007 |
In vivo gene regulation in Salmonella spp. by a salicylate-dependent control circuit.
Topics: 3-Phosphoshikimate 1-Carboxyvinyltransferase; Animals; Aspirin; Bacterial Proteins; beta-Galactosidase; Cell Line, Tumor; Flucytosine; Fluorouracil; Gene Expression; Gene Expression Regulation, Bacterial; Genetic Engineering; Green Fluorescent Proteins; HeLa Cells; Humans; Lac Operon; Macrophages; Mice; Neoplasms; Operon; Promoter Regions, Genetic; Salmonella enterica; Salmonella Infections; Sodium Salicylate; Spleen; Transcription Factors | 2007 |
Pathogens on aspirin: promising research and therapeutic applications.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bacterial Proteins; Flucytosine; Fluorouracil; Gene Expression Regulation, Bacterial; Mice; Neoplasms; Salmonella enterica; Salmonella Infections; Sodium Salicylate | 2007 |
Exogenous cytosine deaminase gene expression in Bifidobacterium breve I-53-8w for tumor-targeting enzyme/prodrug therapy.
Topics: Animals; Antineoplastic Agents; Bifidobacterium; Cell Line, Tumor; Cytosine Deaminase; Drug Delivery Systems; Flucytosine; Fluorouracil; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Plasmids; Prodrugs; Transplantation, Heterologous | 2007 |
Image-guided enzyme/prodrug cancer therapy.
Topics: Animals; Breast Neoplasms; Catalogs, Drug as Topic; Cytosine Deaminase; Female; Flucytosine; Fluorouracil; Humans; Magnetic Resonance Imaging; Mice; Mice, SCID; Neoplasm Transplantation; Prodrugs; Transplantation, Heterologous | 2008 |
Yeast cytosine deaminase mutants with increased thermostability impart sensitivity to 5-fluorocytosine.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Crystallography, X-Ray; Cytosine Deaminase; Enzyme Stability; Escherichia coli; Female; Flucytosine; Fluorouracil; Fungal Proteins; Mice; Mice, Nude; Models, Molecular; Mutation; Prodrugs; Protein Denaturation; Rats; Substrate Specificity; Temperature; Transfection; Xenograft Model Antitumor Assays | 2008 |
Genetic construction, expression, and characterization of a single chain anti-CEA antibody fused to cytosine deaminase from yeast.
Topics: Amino Acid Sequence; Antibodies, Monoclonal; Apoptosis; Blotting, Western; Carcinoembryonic Antigen; Colorectal Neoplasms; Cytosine Deaminase; Electrophoresis, Polyacrylamide Gel; Enzyme-Linked Immunosorbent Assay; Flucytosine; Fluorouracil; Genetic Engineering; Humans; Immunoglobulin Variable Region; Melanoma; Molecular Sequence Data; Recombinant Fusion Proteins; Saccharomyces cerevisiae; Tumor Cells, Cultured | 2008 |
Implication of functional activity for determining therapeutic efficacy of suicide genes in vitro.
Topics: Animals; Apoptosis; Cell Line; Cell Survival; Chromatography, High Pressure Liquid; Curcumin; Cytosine Deaminase; DNA Fragmentation; Drug Synergism; Electroporation; Enzyme-Linked Immunosorbent Assay; Flucytosine; Fluorouracil; Gene Expression Regulation; Genes, Transgenic, Suicide; Genetic Vectors; HT29 Cells; Humans; Pentosyltransferases; Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Transfection | 2008 |
Chemotherapy targeted to cancer tissue potentiates antigen-specific immune response induced by vaccine for in vivo antigen loading and activation of dendritic cells.
Topics: Adenoviridae; Animals; Antigens, Neoplasm; Antineoplastic Agents; Base Sequence; Cancer Vaccines; Dendritic Cells; DNA Primers; Flucytosine; Fluorouracil; Genetic Vectors; Injections, Intralesional; Mice; Neoplasms, Experimental | 2008 |
Cytosine deaminase as a negative selection marker for gene disruption and replacement in the genus Streptomyces and other actinobacteria.
Topics: Actinobacteria; Anti-Bacterial Agents; Cytosine Deaminase; Escherichia coli Proteins; Flucytosine; Fluorouracil; Genetic Vectors; Microbial Sensitivity Tests; Mutagenesis, Insertional; Selection, Genetic | 2009 |
Antitumor efficiency of the cytosine deaminase/5-fluorocytosine suicide gene therapy system on malignant gliomas: an in vivo study.
Topics: Animals; Cell Line, Tumor; Chromatography, High Pressure Liquid; Cytosine Deaminase; DNA Primers; Escherichia coli; Flucytosine; Fluorescent Antibody Technique; Fluorouracil; Genetic Therapy; Glioma; Immunoblotting; Mice; Mice, Nude; Reverse Transcriptase Polymerase Chain Reaction; Tetrazolium Salts; Thiazoles | 2009 |
Adenovirus-mediated cytosine deaminase/5-fluorocytosine suicide gene therapy of human hepatoblastoma in vitro.
Topics: Adenoviridae; Antineoplastic Agents; Cell Line, Tumor; Cytosine Deaminase; Flucytosine; Fluorescent Antibody Technique; Fluorouracil; Genes, Transgenic, Suicide; Genetic Therapy; Genetic Vectors; Hepatoblastoma; Humans; In Vitro Techniques; Liver Neoplasms; Transduction, Genetic | 2009 |
Bystander effect from cytosine deaminase and uracil phosphoribosyl transferase genes in vitro: a partial contribution of gap junctions.
Topics: Bystander Effect; Cell Communication; Cloning, Molecular; Cytosine Deaminase; Flucytosine; Fluorouracil; Gap Junctions; Genetic Therapy; HeLa Cells; Humans; Pentosyltransferases | 2009 |
Expression of the bifunctional suicide gene CDUPRT increases radiosensitization and bystander effect of 5-FC in prostate cancer cells.
Topics: Animals; Blotting, Western; Bystander Effect; Cell Line, Tumor; Coculture Techniques; Cytosine Deaminase; Disease Models, Animal; Flucytosine; Fluorouracil; Gene Expression Regulation, Neoplastic; Magnetic Resonance Spectroscopy; Male; Mice; Mice, Nude; Pentosyltransferases; Probability; Prostatic Neoplasms; Radiation Tolerance; Reference Values; Transfection | 2009 |
Cytosine deaminase-producing human mesenchymal stem cells mediate an antitumor effect in a mouse xenograft model.
Topics: Animals; Antimetabolites, Antineoplastic; Carbocyanines; Cell Line, Tumor; Cell Movement; Cytosine Deaminase; Dose-Response Relationship, Drug; Escherichia coli Proteins; Female; Flucytosine; Fluorescent Dyes; Fluorouracil; Humans; Injections, Intraperitoneal; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Mice; Mice, Nude; Microscopy, Fluorescence; NIH 3T3 Cells; Prodrugs; Stomach Neoplasms; Time Factors; Transfection; Xenograft Model Antitumor Assays | 2009 |
5-Fluoro pyrimidines: labels to probe DNA and RNA secondary structures by 1D 19F NMR spectroscopy.
Topics: Aptamers, Nucleotide; Cytidine; DNA; Flucytosine; Fluorouracil; Nuclear Magnetic Resonance, Biomolecular; Nucleic Acid Conformation; Nucleic Acid Probes; Oligonucleotides; Organophosphorus Compounds; RNA; Thermodynamics | 2009 |
Adipose tissue-derived mesenchymal stem cells expressing prodrug-converting enzyme inhibit human prostate tumor growth.
Topics: Animals; Cell Line, Tumor; Cytosine Deaminase; Flucytosine; Fluorouracil; Humans; Male; Mesenchymal Stem Cells; Mice; Mice, Nude; Pentosyltransferases; Prostatic Neoplasms | 2010 |
Targeted chemotherapy for head and neck cancer with a chimeric oncolytic adenovirus coding for bifunctional suicide protein FCU1.
Topics: Adenoviridae; Animals; Cell Line; Cell Line, Tumor; Cell Survival; Cytosine Deaminase; Female; Flucytosine; Fluorouracil; Genes, Transgenic, Suicide; Genetic Therapy; Genetic Vectors; Head and Neck Neoplasms; Humans; Mice; Mice, Inbred Strains; Mice, Nude; Oncolytic Viruses; Pentosyltransferases; Recombinant Fusion Proteins; Transduction, Genetic; Xenograft Model Antitumor Assays | 2010 |
The growth of brain tumors can be suppressed by multiple transplantation of mesenchymal stem cells expressing cytosine deaminase.
Topics: Adolescent; Animals; Brain Neoplasms; Bystander Effect; Child; Chromatography, High Pressure Liquid; Cytosine Deaminase; Flucytosine; Fluorouracil; Genetic Therapy; Humans; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Rats; Rats, Sprague-Dawley; Tumor Cells, Cultured | 2010 |
Molecular mechanisms of resistance to 5-fluorocytosine in laboratory mutants of Candida glabrata.
Topics: Amino Acid Substitution; Antifungal Agents; Candida glabrata; Cytosine Deaminase; DNA Mutational Analysis; Drug Resistance, Fungal; Flucytosine; Fluorouracil; Gene Expression; Mutation, Missense; Pentosyltransferases; Thymidylate Synthase | 2011 |
Comparative evaluation of preclinical in vivo models for the assessment of replicating retroviral vectors for the treatment of glioblastoma.
Topics: Animals; Brain Neoplasms; Bystander Effect; Cytosine Deaminase; Disease Models, Animal; Drug Evaluation, Preclinical; Flucytosine; Fluorouracil; Genes, Transgenic, Suicide; Genetic Therapy; Genetic Vectors; Glioblastoma; Humans; Mice; Mice, Nude; Mice, SCID; Prodrugs; Retroviridae; Transduction, Genetic; Tumor Cells, Cultured; Virus Replication | 2011 |
Nanoplex delivery of siRNA and prodrug enzyme for multimodality image-guided molecular pathway targeted cancer therapy.
Topics: Animals; Bacteria; Base Sequence; Breast Neoplasms; Cell Line, Tumor; Cell Transformation, Neoplastic; Cytosine Deaminase; Drug Carriers; Female; Flucytosine; Fluorouracil; Humans; Magnetic Resonance Imaging; Mice; Models, Molecular; Molecular Imaging; Nanostructures; Prodrugs; Protein Conformation; RNA, Small Interfering; Treatment Outcome | 2010 |
Enhancing VSV oncolytic activity with an improved cytosine deaminase suicide gene strategy.
Topics: Combined Modality Therapy; Cytosine Deaminase; Flucytosine; Fluorouracil; Genes, Transgenic, Suicide; Genetic Therapy; Humans; Oncolytic Viruses; Pentosyltransferases; Recombinant Fusion Proteins; Vesiculovirus | 2011 |
Annexin V-targeted enzyme prodrug therapy using cytosine deaminase in combination with 5-fluorocytosine.
Topics: Annexin A5; Antimetabolites; Aorta; Breast Neoplasms; Cell Survival; Cells, Cultured; Combined Modality Therapy; Cytosine Deaminase; Endothelium, Vascular; Female; Flucytosine; Fluorouracil; Genetic Therapy; Humans; Phosphatidylserines; Prodrugs; Recombinant Fusion Proteins | 2011 |
Genetically engineered stem cells expressing cytosine deaminase and interferon-β migrate to human lung cancer cells and have potentially therapeutic anti-tumor effects.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Communication; Cell Line, Tumor; Cell Migration Assays; Cell Movement; Chemotactic Factors; Cytosine Deaminase; Drug Delivery Systems; Flucytosine; Fluorouracil; Genetic Engineering; Genetic Therapy; Humans; Interferon-beta; Lung Neoplasms; Prodrugs; Stem Cells | 2011 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fluorouracil; Genetic Therapy; Genetic Vectors; Glioma; Leukemia Virus, Murine; Mice; Mice, Inbred BALB C; Survival Analysis; Tumor Cells, Cultured | 2012 |
Chemovirotherapy for head and neck squamous cell carcinoma with EGFR-targeted and CD/UPRT-armed oncolytic measles virus.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Chlorocebus aethiops; Cytosine Deaminase; ErbB Receptors; Female; Flucytosine; Fluorouracil; Head and Neck Neoplasms; Humans; Measles virus; Mice; Mice, Inbred NOD; Mice, SCID; Oncolytic Virotherapy; Pentosyltransferases; Prodrugs; Squamous Cell Carcinoma of Head and Neck; Vero Cells; Xenograft Model Antitumor Assays | 2012 |
Oncolytic herpes simplex virus expressing yeast cytosine deaminase: relationship between viral replication, transgene expression, prodrug bioactivation.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Chlorocebus aethiops; Colonic Neoplasms; Cytosine Deaminase; Drug Administration Schedule; Flucytosine; Fluorouracil; Genetic Therapy; Genetic Vectors; HT29 Cells; Humans; Male; Mice; Mice, Inbred BALB C; Oncolytic Virotherapy; Prodrugs; Simplexvirus; Transgenes; Virus Replication; Xenograft Model Antitumor Assays; Yeasts | 2012 |
Interaction of endothelial progenitor cells expressing cytosine deaminase in tumor tissues and 5-fluorocytosine administration suppresses growth of 5-fluorouracil-sensitive liver cancer in mice.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cytosine Deaminase; Endothelial Cells; Flucytosine; Fluorouracil; Genetic Therapy; Humans; Liver Neoplasms; Male; Mice; Mice, Nude; Microscopy, Confocal; Prodrugs; Rats; Reverse Transcriptase Polymerase Chain Reaction; Stem Cells; Transfection | 2012 |
Antitumor effects of genetically engineered stem cells expressing yeast cytosine deaminase in lung cancer brain metastases via their tumor-tropic properties.
Topics: Animals; Brain Neoplasms; Cell Survival; Cytosine Deaminase; Flucytosine; Fluorouracil; Genetic Engineering; Genetic Therapy; Humans; Lung Neoplasms; Mice; Neural Stem Cells; Saccharomyces cerevisiae; Xenograft Model Antitumor Assays | 2012 |
Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytosine Deaminase; Flucytosine; Fluorouracil; Fungal Proteins; Gene Expression; Genetic Therapy; Genetic Vectors; Humans; Leukemia Virus, Murine; Mice; Neoplasm Transplantation; Neoplasms, Experimental; Prodrugs; Rats; RNA Stability; Transgenes | 2012 |
Effects of genetically engineered stem cells expressing cytosine deaminase and interferon-beta or carboxyl esterase on the growth of LNCaP rrostate cancer cells.
Topics: Animals; Camptothecin; Carboxylesterase; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Coculture Techniques; Cytosine Deaminase; Flucytosine; Fluorouracil; Genetic Engineering; Humans; Interferon-beta; Irinotecan; Male; Prodrugs; Prostatic Neoplasms; Rabbits; Stem Cells | 2012 |
Synthesis of cyclopentanyl carbocyclic 5-fluorocytosine ((-)-5-fluorocarbodine) using a facially selective hydrogenation approach.
Topics: Cyclization; Cyclopentanes; Cytidine; Flucytosine; Fluorouracil; Hydrogenation; Molecular Structure; Stereoisomerism | 2013 |
Repurposing the antimycotic drug flucytosine for suppression of Pseudomonas aeruginosa pathogenicity.
Topics: Animals; Antifungal Agents; Bacterial Proteins; Down-Regulation; Flucytosine; Fluorouracil; Gene Expression Regulation, Bacterial; Genes, Bacterial; Humans; Male; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Oligopeptides; Pseudomonas aeruginosa; Pseudomonas Infections; Sigma Factor; Transcription, Genetic; Virulence | 2013 |
Neural stem cell-mediated enzyme/prodrug therapy for glioma: preclinical studies.
Topics: Animals; Cell Line; Cytosine Deaminase; Female; Flow Cytometry; Flucytosine; Fluorouracil; Glioma; Humans; Male; Mice; Mice, Nude; Neural Stem Cells; Prodrugs | 2013 |
[Antitumor activity of the recombinant rClone30-CD/5-FC system].
Topics: Animals; Antimetabolites, Antineoplastic; Cell Death; Chick Embryo; Cytosine Deaminase; Escherichia coli; Flucytosine; Fluorouracil; Genetic Vectors; Hep G2 Cells; Humans; Lethal Dose 50; Liver Neoplasms, Experimental; Mice; Newcastle disease virus; Plasmids; Recombinant Proteins; Transfection; Tumor Burden | 2013 |
Pancreatic tumor mass in a xenograft mouse model is decreased by treatment with therapeutic stem cells following introduction of therapeutic genes.
Topics: Animals; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Movement; Cell Proliferation; Cells, Cultured; Cytosine Deaminase; Dermis; Fibroblasts; Flucytosine; Fluorouracil; Genetic Engineering; Genetic Therapy; Humans; Interferon-beta; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Prodrugs; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stem Cells; Xenograft Model Antitumor Assays | 2013 |
Adenosine potentiates the therapeutic effects of neural stem cells expressing cytosine deaminase against metastatic brain tumors.
Topics: Adenosine; Animals; Antimetabolites, Antineoplastic; Apoptosis; Blood-Brain Barrier; Blotting, Western; Brain Neoplasms; Breast Neoplasms; Cell Proliferation; Cells, Cultured; Cytosine Deaminase; Drug Synergism; Female; Fetus; Flucytosine; Fluorouracil; Genetic Engineering; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neural Stem Cells; Prodrugs; Vasodilator Agents; Xenograft Model Antitumor Assays | 2013 |
Enhancement of anti-tumor activity of Newcastle disease virus by the synergistic effect of cytosine deaminase.
Topics: Adenoviridae; Animals; Antimetabolites; Combined Modality Therapy; Cytosine Deaminase; Drug Synergism; Flucytosine; Fluorouracil; Genetic Therapy; Genetic Vectors; Humans; Liver Neoplasms, Experimental; Mice; Newcastle disease virus; Oncolytic Virotherapy; Survival Rate; Tumor Cells, Cultured | 2013 |
Augmenting podocyte injury promotes advanced diabetic kidney disease in Akita mice.
Topics: Albuminuria; Animals; Antimetabolites; Cytosine Deaminase; Diabetic Nephropathies; Disease Models, Animal; Flucytosine; Fluorouracil; Gene Expression; Kidney; Mice; Podocytes; Prodrugs | 2014 |
Deletion of the uracil permease gene confers cross-resistance to 5-fluorouracil and azoles in Candida lusitaniae and highlights antagonistic interaction between fluorinated nucleotides and fluconazole.
Topics: Antifungal Agents; Azoles; Biological Transport; Candida; Crosses, Genetic; Drug Antagonism; Drug Resistance, Fungal; Flucytosine; Fluorouracil; Fungal Proteins; Gene Deletion; Gene Expression Regulation, Fungal; Microbial Sensitivity Tests; Nucleobase Transport Proteins; Nucleotide Transport Proteins; Sterol 14-Demethylase; Uracil; Uridine | 2014 |
Pulsed versus continuous application of the prodrug 5-fluorocytosine to enhance the oncolytic effectiveness of a measles vaccine virus armed with a suicide gene.
Topics: Antimetabolites; Cell Line, Tumor; Cell Survival; Cytosine Deaminase; Flucytosine; Fluorouracil; HCT116 Cells; Humans; Measles Vaccine; Measles virus; Oncolytic Virotherapy; Prodrugs | 2014 |
Annexin V-Directed Enzyme Prodrug Therapy Plus Docetaxel for the Targeted Treatment of Pancreatic Cancer.
Topics: Adenine; Adenocarcinoma; Annexin A5; Antineoplastic Combined Chemotherapy Protocols; Carbon-Sulfur Lyases; Cell Death; Cell Line, Tumor; Cytosine Deaminase; Docetaxel; Dose-Response Relationship, Drug; Enzymes; Flucytosine; Fluorouracil; Humans; Methanol; Molecular Targeted Therapy; Organoselenium Compounds; Pancreatic Neoplasms; Prodrugs; Purine-Nucleoside Phosphorylase; Recombinant Fusion Proteins; Selenomethionine; Taxoids; Tubulin Modulators; Vidarabine | 2015 |
Additional effects of engineered stem cells expressing a therapeutic gene and interferon-β in a xenograft mouse model of endometrial cancer.
Topics: Animals; Cell Line, Tumor; Combined Modality Therapy; Cytosine Deaminase; Endometrial Neoplasms; Female; Flucytosine; Fluorouracil; Genetic Therapy; Humans; Injections, Intraperitoneal; Interferon-beta; Mice; Neural Stem Cells; Receptor, Interferon alpha-beta; Stem Cell Transplantation; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2015 |
Enhanced EJ Cell Killing of (125)I Radiation by Combining with Cytosine Deaminase Gene Therapy Regulated by Synthetic Radio-Responsive Promoter.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Survival; Cytosine Deaminase; Early Growth Response Protein 1; Escherichia coli Proteins; Flucytosine; Fluorouracil; Genes, Synthetic; Genetic Therapy; Genetic Vectors; Green Fluorescent Proteins; Humans; Iodine Radioisotopes; Lentivirus; Promoter Regions, Genetic; Radiation Tolerance; Recombinant Fusion Proteins; Tandem Repeat Sequences; Transduction, Genetic; Urinary Bladder Neoplasms | 2015 |
Cleavage of DNA containing 5-fluorocytosine or 5-fluorouracil by type II restriction endonucleases.
Topics: Deoxyribonucleases, Type II Site-Specific; DNA; DNA Cleavage; Flucytosine; Fluorouracil; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2015 |
Targeted Treatment of Experimental Spinal Cord Glioma With Dual Gene-Engineered Human Neural Stem Cells.
Topics: Animals; Cytosine Deaminase; Flucytosine; Fluorouracil; Ganciclovir; Genetic Engineering; Genetic Therapy; Glioma; Humans; Neural Stem Cells; Rats; Spinal Cord Neoplasms; Stem Cell Transplantation; Thymidine Kinase; Xenograft Model Antitumor Assays | 2016 |
Expression of Therapeutic Gene FCU1 Sensitizes Pancreatic Cancer Cells to 5-Fluorocytosine and Enhances the Cytotoxic Effect of 5-Fluorouracil.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytosine Deaminase; Drug Resistance, Neoplasm; Flucytosine; Fluorouracil; Gene Expression; Genetic Vectors; Humans; Insulin-Secreting Cells; Lentivirus; Pentosyltransferases; Plasmids; Recombinant Fusion Proteins; Transduction, Genetic | 2016 |
Antitumor efficacy of combined gene and radiotherapy in animals.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; Combined Modality Therapy; Cytomegalovirus; Flucytosine; Fluorouracil; Genes, Transgenic, Suicide; Genetic Therapy; Genetic Vectors; Granulocyte-Macrophage Colony-Stimulating Factor; Mice, Inbred BALB C; Neoplasm Grading; Neoplasm Transplantation; Treatment Outcome; Tumor Burden | 2016 |
Simultaneous detection of 5-fluorocytosine and 5-fluorouracil in human cells carrying CD/5-FC suicide gene system by using capillary zone electrophoresis.
Topics: Electrophoresis, Capillary; Flucytosine; Fluorouracil; Genes, Transgenic, Suicide; HEK293 Cells; Humans; Limit of Detection; Linear Models; Reproducibility of Results | 2018 |
Prodrug suicide gene therapy for cancer targeted intracellular by mesenchymal stem cell exosomes.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cytosine Deaminase; Exosomes; Flucytosine; Fluorouracil; Fungal Proteins; Genes, Transgenic, Suicide; Genetic Therapy; Humans; Mesenchymal Stem Cells; Pentosyltransferases; Prodrugs; Yeasts | 2019 |
Olfactory Ensheathing Cells: A Trojan Horse for Glioma Gene Therapy.
Topics: Administration, Intranasal; Animals; Cytosine Deaminase; Female; Flucytosine; Fluorouracil; Genetic Therapy; Glioma; Humans; Male; Mice; Mice, Inbred C57BL; Olfactory Bulb; Pentosyltransferases; Transgenes; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Pharmacological inhibition of pigmentation in Cryptococcus.
Topics: Antifungal Agents; Cryptococcus gattii; DNA Mutational Analysis; Drug Evaluation, Preclinical; Flucytosine; Fluorouracil; Genetic Testing; Melanins; Mutagenesis, Insertional | 2019 |
Photochemical Internalization Enhanced Nonviral Suicide Gene Therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cytosine Deaminase; Flucytosine; Fluorouracil; Genes, Transgenic, Suicide; Genetic Therapy; Glioma; Neoplasms; Photochemotherapy; Prodrugs; Rats | 2019 |
Isocytosine deaminase Vcz as a novel tool for the prodrug cancer therapy.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Brain Neoplasms; Caco-2 Cells; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Cytosine; Cytosine Deaminase; Flucytosine; Fluorouracil; Genes, Transgenic, Suicide; Genetic Therapy; Genetic Vectors; Glioblastoma; Humans; Lentivirus; Mesenchymal Stem Cells; Mice; Nucleoside Deaminases; Prodrugs | 2019 |
Activity and Impact on Resistance Development of Two Antivirulence Fluoropyrimidine Drugs in
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Flucytosine; Fluorouracil; Humans; Pseudomonas aeruginosa; Virulence | 2019 |
Activity of base analogues (5-fluorouracil, 5-flucytosine) against planktonic cells and mature biofilm of Candida yeast. Effect of combination with folinic acid.
Topics: Antifungal Agents; Biofilms; Candida albicans; Candida glabrata; Candidiasis; Drug Resistance, Fungal; Flucytosine; Fluorouracil; Gentian Violet; Leucovorin; Microbial Sensitivity Tests; Microbial Viability | 2019 |
Suicide gene‑armed measles vaccine virus for the treatment of AML.
Topics: Adult; Aged; Combined Modality Therapy; Female; Flucytosine; Fluorouracil; Follow-Up Studies; Genes, Transgenic, Suicide; Humans; Leukemia, Myeloid, Acute; Male; Measles virus; Membrane Cofactor Protein; Middle Aged; Oncolytic Virotherapy; Prodrugs; Prognosis; Young Adult | 2019 |
Enzymes Photo-Cross-Linked to Live Cell Receptors Retain Activity and EGFR Inhibition after Both Internalization and Recycling.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cytosine Deaminase; ErbB Receptors; Female; Flucytosine; Fluorouracil; Humans; Prodrugs; Protein Kinase Inhibitors; Recombinant Fusion Proteins | 2020 |
Determination of 5-fluorocytosine, 5-fluorouracil, and 5-fluorouridine in hospital wastewater by liquid chromatography-mass spectrometry.
Topics: Chromatography, High Pressure Liquid; Flucytosine; Fluorouracil; Hospitals; Molecular Structure; Solid Phase Extraction; Tandem Mass Spectrometry; Uridine; Wastewater; Water Pollutants, Chemical | 2020 |
Intracellular prodrug gene therapy for cancer mediated by tumor cell suicide gene exosomes.
Topics: Animals; Antineoplastic Agents; Cell Engineering; Cell Line, Tumor; Culture Media, Conditioned; Cytosine Deaminase; Exosomes; Flucytosine; Fluorouracil; Fungal Proteins; Genes, Transgenic, Suicide; Genetic Therapy; Genetic Vectors; Humans; Mice; Neoplasms; Pentosyltransferases; Prodrugs; Recombinant Fusion Proteins; Retroviridae; Transduction, Genetic; Xenograft Model Antitumor Assays | 2021 |
Assessing and Overcoming Resistance Phenomena against a Genetically Modified Vaccinia Virus in Selected Cancer Cell Lines.
Topics: Antineoplastic Agents; Cell Death; Cell Line, Tumor; Combined Modality Therapy; Cytosine Deaminase; Drug Resistance, Neoplasm; Flucytosine; Fluorouracil; Genetic Engineering; Humans; Oncolytic Virotherapy; Oncolytic Viruses; Prodrugs; Vaccinia virus; Viral Proteins | 2020 |
Development of LC-HRMS methods for evaluation of metabolic conversion of 5-fluorocytosine at GDEPT procedure.
Topics: Chromatography, Liquid; Cytosine Deaminase; Flucytosine; Fluorouracil; Mass Spectrometry; Prodrugs | 2021 |
Pharmacokinetics and tolerance of repeated oral administration of 5-fluorocytosine in healthy dogs.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Dog Diseases; Dogs; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; Female; Flucytosine; Fluorouracil; Male | 2021 |
Affibody-conjugated 5-fluorouracil prodrug system preferentially targets and inhibits HER2-expressing cancer cells.
Topics: Amino Acid Sequence; Antineoplastic Agents; Biotransformation; Cell Line, Tumor; Cytosine Deaminase; Flucytosine; Fluorouracil; Gene Expression; Humans; Inhibitory Concentration 50; Molecular Targeted Therapy; Prodrugs; Protein Binding; Receptor, ErbB-2; Recombinant Fusion Proteins; Saccharomyces cerevisiae Proteins | 2021 |
Enzyme Prodrug Therapy with Photo-Cross-Linkable Anti-EGFR Affibodies Conjugated to Upconverting Nanoparticles.
Topics: Animals; Antineoplastic Agents; Caco-2 Cells; Cell Line, Tumor; Cytosine Deaminase; EGF Family of Proteins; Flucytosine; Fluorouracil; Humans; Mice; Mice, Nude; Nanoparticles; Prodrugs | 2022 |
The fungal expel of 5-fluorocytosine derived fluoropyrimidines mitigates its antifungal activity and generates a cytotoxic environment.
Topics: Animals; Antifungal Agents; Antimetabolites; Antineoplastic Agents; Aspergillosis; Aspergillus fumigatus; Drug Resistance, Fungal; Flucytosine; Fluorouracil; Humans; Mammals | 2022 |
Suicide-Gene-Modified Extracellular Vesicles of Human Primary Uveal Melanoma in Future Therapies.
Topics: Animals; Extracellular Vesicles; Flucytosine; Fluorouracil; Humans; Melanoma; Skin Neoplasms; Uveal Neoplasms | 2023 |
Correlation of antifungal susceptibility and sequence types within Cryptococcus neoformans VNI from HIV patients, and ERG11 gene polymorphism.
Topics: Amphotericin B; Antifungal Agents; Cryptococcosis; Cryptococcus neoformans; Democratic Republic of the Congo; Drug Resistance, Fungal; Fluconazole; Flucytosine; Fluorouracil; HIV Infections; Humans; Microbial Sensitivity Tests; Polymorphism, Genetic | 2023 |